<?xml version='1.0' encoding='UTF-8'?>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS One</journal-id><journal-id journal-id-type="pmc-domain-id">440</journal-id><journal-id journal-id-type="pmc-domain">plosone</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>PLOS</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC7591030</article-id><article-id pub-id-type="pmcid-ver">PMC7591030.1</article-id><article-id pub-id-type="pmcaid">7591030</article-id><article-id pub-id-type="pmcaiid">7591030</article-id><article-id pub-id-type="pmid">33108404</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0236384</article-id><article-id pub-id-type="publisher-id">PONE-D-20-20650</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Nervous System</subject><subj-group><subject>Central Nervous System</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Nervous System</subject><subj-group><subject>Central Nervous System</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Mental Health and Psychiatry</subject><subj-group><subject>Dementia</subject><subj-group><subject>Frontotemporal Dementia</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Neurology</subject><subj-group><subject>Dementia</subject><subj-group><subject>Frontotemporal Dementia</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Neuroscience</subject><subj-group><subject>Brain Mapping</subject><subj-group><subject>Brain Morphometry</subject><subj-group><subject>Diffusion Tensor Imaging</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Diagnostic Medicine</subject><subj-group><subject>Diagnostic Radiology</subject><subj-group><subject>Magnetic Resonance Imaging</subject><subj-group><subject>Brain Morphometry</subject><subj-group><subject>Diffusion Tensor Imaging</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Imaging Techniques</subject><subj-group><subject>Diagnostic Radiology</subject><subj-group><subject>Magnetic Resonance Imaging</subject><subj-group><subject>Brain Morphometry</subject><subj-group><subject>Diffusion Tensor Imaging</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Radiology and Imaging</subject><subj-group><subject>Diagnostic Radiology</subject><subj-group><subject>Magnetic Resonance Imaging</subject><subj-group><subject>Brain Morphometry</subject><subj-group><subject>Diffusion Tensor Imaging</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Imaging Techniques</subject><subj-group><subject>Neuroimaging</subject><subj-group><subject>Brain Morphometry</subject><subj-group><subject>Diffusion Tensor Imaging</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Neuroscience</subject><subj-group><subject>Neuroimaging</subject><subj-group><subject>Brain Morphometry</subject><subj-group><subject>Diffusion Tensor Imaging</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Body Fluids</subject><subj-group><subject>Blood</subject><subj-group><subject>Blood Plasma</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Body Fluids</subject><subj-group><subject>Blood</subject><subj-group><subject>Blood Plasma</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Body Fluids</subject><subj-group><subject>Blood</subject><subj-group><subject>Blood Plasma</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Body Fluids</subject><subj-group><subject>Cerebrospinal Fluid</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Body Fluids</subject><subj-group><subject>Cerebrospinal Fluid</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Body Fluids</subject><subj-group><subject>Cerebrospinal Fluid</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Nervous System</subject><subj-group><subject>Cerebrospinal Fluid</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Nervous System</subject><subj-group><subject>Cerebrospinal Fluid</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteins</subject><subj-group><subject>Cytoskeletal Proteins</subject><subj-group><subject>Neurofilaments</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Cellular Types</subject><subj-group><subject>Animal Cells</subject><subj-group><subject>Neurons</subject><subj-group><subject>Nerve Fibers</subject><subj-group><subject>Axons</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Neuroscience</subject><subj-group><subject>Cellular Neuroscience</subject><subj-group><subject>Neurons</subject><subj-group><subject>Nerve Fibers</subject><subj-group><subject>Axons</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Biomarkers</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Plasma neurofilament light protein correlates with diffusion tensor imaging metrics in frontotemporal dementia</article-title><alt-title alt-title-type="running-head">NfL levels associate with fractional anisotropy in bvFTD</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5404-8788</contrib-id><name name-style="western"><surname>Spotorno</surname><given-names initials="N">Nicola</given-names></name><role content-type="https://casrai.org/credit/">Conceptualization</role><role content-type="https://casrai.org/credit/">Formal analysis</role><role content-type="https://casrai.org/credit/">Methodology</role><role content-type="https://casrai.org/credit/">Visualization</role><role content-type="https://casrai.org/credit/">Writing – original draft</role><role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lindberg</surname><given-names initials="O">Olof</given-names></name><role content-type="https://casrai.org/credit/">Data curation</role><role content-type="https://casrai.org/credit/">Formal analysis</role><role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nilsson</surname><given-names initials="C">Christer</given-names></name><role content-type="https://casrai.org/credit/">Conceptualization</role><role content-type="https://casrai.org/credit/">Investigation</role><role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role><xref ref-type="aff" rid="aff004"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Landqvist Waldö</surname><given-names initials="M">Maria</given-names></name><role content-type="https://casrai.org/credit/">Conceptualization</role><role content-type="https://casrai.org/credit/">Investigation</role><role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role><xref ref-type="aff" rid="aff005"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>van Westen</surname><given-names initials="D">Danielle</given-names></name><role content-type="https://casrai.org/credit/">Conceptualization</role><role content-type="https://casrai.org/credit/">Funding acquisition</role><role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role><xref ref-type="aff" rid="aff006"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nilsson</surname><given-names initials="K">Karin</given-names></name><role content-type="https://casrai.org/credit/">Data curation</role><role content-type="https://casrai.org/credit/">Investigation</role><role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Vestberg</surname><given-names initials="S">Susanna</given-names></name><role content-type="https://casrai.org/credit/">Data curation</role><role content-type="https://casrai.org/credit/">Investigation</role><role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role><xref ref-type="aff" rid="aff007"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Englund</surname><given-names initials="E">Elisabet</given-names></name><role content-type="https://casrai.org/credit/">Conceptualization</role><role content-type="https://casrai.org/credit/">Investigation</role><role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role><xref ref-type="aff" rid="aff008"><sup>8</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zetterberg</surname><given-names initials="H">Henrik</given-names></name><role content-type="https://casrai.org/credit/">Conceptualization</role><role content-type="https://casrai.org/credit/">Data curation</role><role content-type="https://casrai.org/credit/">Methodology</role><role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role><xref ref-type="aff" rid="aff009"><sup>9</sup></xref><xref ref-type="aff" rid="aff010"><sup>10</sup></xref><xref ref-type="aff" rid="aff011"><sup>11</sup></xref><xref ref-type="aff" rid="aff012"><sup>12</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Blennow</surname><given-names initials="K">Kaj</given-names></name><role content-type="https://casrai.org/credit/">Conceptualization</role><role content-type="https://casrai.org/credit/">Formal analysis</role><role content-type="https://casrai.org/credit/">Methodology</role><role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role><xref ref-type="aff" rid="aff009"><sup>9</sup></xref><xref ref-type="aff" rid="aff010"><sup>10</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lätt</surname><given-names initials="J">Jimmy</given-names></name><role content-type="https://casrai.org/credit/">Data curation</role><role content-type="https://casrai.org/credit/">Methodology</role><role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role><xref ref-type="aff" rid="aff013"><sup>13</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Markus</surname><given-names initials="N">Nilsson</given-names></name><role content-type="https://casrai.org/credit/">Data curation</role><role content-type="https://casrai.org/credit/">Methodology</role><role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role><xref ref-type="aff" rid="aff006"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lars-Olof</surname><given-names initials="W">Wahlund</given-names></name><role content-type="https://casrai.org/credit/">Funding acquisition</role><role content-type="https://casrai.org/credit/">Resources</role><role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Alexander</surname><given-names initials="S">Santillo</given-names></name><role content-type="https://casrai.org/credit/">Conceptualization</role><role content-type="https://casrai.org/credit/">Data curation</role><role content-type="https://casrai.org/credit/">Funding acquisition</role><role content-type="https://casrai.org/credit/">Investigation</role><role content-type="https://casrai.org/credit/">Project administration</role><role content-type="https://casrai.org/credit/">Supervision</role><role content-type="https://casrai.org/credit/">Writing – original draft</role><role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>Department of Neurology, Penn Frontotemporal Degeneration Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, United States of America</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Department of Clinical Sciences, Clinical Memory Research Unit, Lund University, Malmö, Sweden</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>Division of Clinical Geriatrics, Karolinska Institute, Stockholm, Sweden</addr-line></aff><aff id="aff004"><label>4</label>
<addr-line>Division of Neurology, Department of Clinical Sciences, Lund University, Lund, Sweden</addr-line></aff><aff id="aff005"><label>5</label>
<addr-line>Department of clinical Sciences, Clinical Sciences Helsingborg, Lund, Lund University, Lund, Sweden</addr-line></aff><aff id="aff006"><label>6</label>
<addr-line>Department of Diagnostic Radiology, Clinical Sciences, Lund University, Lund, Sweden</addr-line></aff><aff id="aff007"><label>7</label>
<addr-line>Department of Psychology, Lund University, Lund, Sweden</addr-line></aff><aff id="aff008"><label>8</label>
<addr-line>Division of Pathology, Department of Clinical Sciences, Lund, Sweden</addr-line></aff><aff id="aff009"><label>9</label>
<addr-line>Department of Psychiatry and Neurochemistry, Institute of Neuroscience &amp; Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden</addr-line></aff><aff id="aff010"><label>10</label>
<addr-line>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden</addr-line></aff><aff id="aff011"><label>11</label>
<addr-line>Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, United Kingdom</addr-line></aff><aff id="aff012"><label>12</label>
<addr-line>UK Dementia Research Institute at UCL, London, United Kingdom</addr-line></aff><aff id="aff013"><label>13</label>
<addr-line>Center for Medical Imaging and Physiology, Skåne University Hospital, Lund, Sweden</addr-line></aff><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Najbauer</surname><given-names initials="J">Joseph</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>University of Pécs Medical School, HUNGARY</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>HZ has served at scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed and CogRx, has given lectures in symposia sponsored by Fujirebio, Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. KB has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Roche Diagnostics, and Siemens Healthineers, and is also a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS). These do not alter our adherence to PLOS ONE policies on sharing data and materials.</p></fn><corresp id="cor001">* E-mail: <email>nicola.spotorno@pennmedicine.upenn.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>27</day><month>10</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>15</volume><issue>10</issue><issue-id pub-id-type="pmc-issue-id">366205</issue-id><elocation-id>e0236384</elocation-id><history><date date-type="received"><day>3</day><month>7</month><year>2020</year></date><date date-type="accepted"><day>12</day><month>10</month><year>2020</year></date></history><pub-history><event event-type="pmc-release"><date><day>27</day><month>10</month><year>2020</year></date></event><event event-type="pmc-live"><date><day>30</day><month>10</month><year>2020</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-04-28 23:25:14.477"><day>28</day><month>04</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>© 2020 Spotorno et al</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Spotorno et al</copyright-holder><license xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="pone.0236384.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="pone.0236384.pdf"/><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="editor-report" xml:lang="en" ext-link-type="doi" xlink:href="10.1371/journal.pone.0236384"><pub-id pub-id-type="doi">10.1371/journal.pone.0236384</pub-id></related-article><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="reviewed-article" xml:lang="en" ext-link-type="doi" xlink:href="10.1371/journal.pone.0236384"><pub-id pub-id-type="doi">10.1371/journal.pone.0236384</pub-id></related-article><abstract><p>Neurofilaments are structural components of neurons and are particularly abundant in highly myelinated axons. The levels of neurofilament light chain (NfL) in both cerebrospinal fluid (CSF) and plasma have been related to degeneration in several neurodegenerative conditions including frontotemporal dementia (FTD) and NfL is currently considered as the most promising diagnostic and prognostic fluid biomarker in FTD. Although the location and function of filaments in the healthy nervous system suggests a link between increased NfL and white matter degeneration, such a claim has not been fully elucidated <italic toggle="yes">in vivo</italic>, especially in the context of FTD. The present study provides evidence of an association between the plasma levels of NfL and white matter involvement in behavioral variant FTD (bvFTD) by relating plasma concentration of NfL to diffusion tensor imaging (DTI) metrics in a group of 20 bvFTD patients. The results of both voxel-wise and tract specific analysis showed that increased plasma NfL concentration is associated with a reduction in fractional anisotropy (FA) in a widespread set of white matter tracts including the superior longitudinal fasciculus, the fronto-occipital fasciculus the anterior thalamic radiation and the dorsal cingulum bundle. Plasma NfL concentration also correlated with cortical thinning in a portion of the right medial prefrontal cortex and of the right lateral orbitofrontal cortex. These results support the hypothesis that blood NfL levels reflect the global level of neurodegeneration in bvFTD and help to advance our understanding of the association between this blood biomarker for FTD and the disease process.</p></abstract><funding-group><award-group id="award001"><funding-source><institution>Schörling foundation</institution></funding-source></award-group><award-group id="award002"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000049</institution-id><institution>National Institute on Aging</institution></institution-wrap></funding-source><award-id>AG052943, AG017586</award-id></award-group><award-group id="award003"><funding-source><institution>Swedish Society for Medical Research</institution></funding-source><principal-award-recipient><name name-style="western"><surname>Alexander</surname><given-names>Santillo</given-names></name></principal-award-recipient></award-group><award-group id="award004"><funding-source><institution>Benthe Rexhed Gersteds foundation</institution></funding-source><principal-award-recipient><name name-style="western"><surname>Alexander</surname><given-names>Santillo</given-names></name></principal-award-recipient></award-group><award-group id="award005"><funding-source><institution>Bundy Academy</institution></funding-source><principal-award-recipient><name name-style="western"><surname>Alexander</surname><given-names>Santillo</given-names></name></principal-award-recipient></award-group><award-group id="award006"><funding-source><institution>Strategic Research Area MultiPark</institution></funding-source><principal-award-recipient><name name-style="western"><surname>Alexander</surname><given-names>Santillo</given-names></name></principal-award-recipient></award-group><award-group id="award007"><funding-source><institution>Region Skåne</institution></funding-source><principal-award-recipient><name name-style="western"><surname>Alexander</surname><given-names>Santillo</given-names></name></principal-award-recipient></award-group><award-group id="award008"><funding-source><institution>Lund University</institution></funding-source><principal-award-recipient><name name-style="western"><surname>Alexander</surname><given-names>Santillo</given-names></name></principal-award-recipient></award-group><award-group id="award009"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100004063</institution-id><institution>Knut och Alice Wallenbergs Stiftelse</institution></institution-wrap></funding-source><principal-award-recipient><name name-style="western"><surname>Zetterberg</surname><given-names>Henrik</given-names></name></principal-award-recipient></award-group><award-group id="award010"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100004359</institution-id><institution>Vetenskapsrådet</institution></institution-wrap></funding-source><award-id>#2018-02532</award-id><principal-award-recipient><name name-style="western"><surname>Zetterberg</surname><given-names>Henrik</given-names></name></principal-award-recipient></award-group><award-group id="award011"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100010663</institution-id><institution>H2020 European Research Council</institution></institution-wrap></funding-source><award-id>#681712</award-id><principal-award-recipient><name name-style="western"><surname>Zetterberg</surname><given-names>Henrik</given-names></name></principal-award-recipient></award-group><award-group id="award012"><funding-source><institution>Swedish State Support for Clinical Research</institution></funding-source><award-id>#ALFGBG-720931</award-id><principal-award-recipient><name name-style="western"><surname>Zetterberg</surname><given-names>Henrik</given-names></name></principal-award-recipient></award-group><award-group id="award013"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100002565</institution-id><institution>Alzheimer's Drug Discovery Foundation</institution></institution-wrap></funding-source><award-id>#201809-2016862</award-id><principal-award-recipient><name name-style="western"><surname>Zetterberg</surname><given-names>Henrik</given-names></name></principal-award-recipient></award-group><award-group id="award014"><funding-source><institution>UK Dementia Research Institute at the University College of London</institution></funding-source><principal-award-recipient><name name-style="western"><surname>Zetterberg</surname><given-names>Henrik</given-names></name></principal-award-recipient></award-group><award-group id="award015"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100004359</institution-id><institution>Vetenskapsrådet</institution></institution-wrap></funding-source><award-id>#2017-00915</award-id><principal-award-recipient><name name-style="western"><surname>Blennow</surname><given-names>Kaj</given-names></name></principal-award-recipient></award-group><award-group id="award016"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100002565</institution-id><institution>Alzheimer's Drug Discovery Foundation</institution></institution-wrap></funding-source><award-id>Alzheimer Drug Discovery Foundation</award-id><principal-award-recipient><name name-style="western"><surname>Blennow</surname><given-names>Kaj</given-names></name></principal-award-recipient></award-group><award-group id="award017"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100008599</institution-id><institution>Alzheimerfonden</institution></institution-wrap></funding-source><award-id>#AF-742881</award-id><principal-award-recipient><name name-style="western"><surname>Blennow</surname><given-names>Kaj</given-names></name></principal-award-recipient></award-group><award-group id="award018"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100003792</institution-id><institution>Hjärnfonden</institution></institution-wrap></funding-source><award-id>#FO2017-0243</award-id><principal-award-recipient><name name-style="western"><surname>Blennow</surname><given-names>Kaj</given-names></name></principal-award-recipient></award-group><award-group id="award019"><funding-source><institution>Swedish state under the agreement between the Swedish government and the County Councils</institution></funding-source><award-id>#ALFGBG-715986</award-id><principal-award-recipient><name name-style="western"><surname>Blennow</surname><given-names>Kaj</given-names></name></principal-award-recipient></award-group><award-group id="award020"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100013278</institution-id><institution>EU Joint Programme – Neurodegenerative Disease Research</institution></institution-wrap></funding-source><award-id>JPND2019-466-236</award-id><principal-award-recipient><name name-style="western"><surname>Blennow</surname><given-names>Kaj</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NS, OL, LOW and AS were all supported by the Schörling foundation. NS is also supported by the National Institute on Aging (NIA), grant numbers: AG052943, AG017586. AS is also supported by the Swedish Society for Medical Research, The Benthe Rexhed Gersteds foundation, The Bundy Academy, The Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson’s disease) at Lund University, and Region Skåne. HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532), the European Research Council (#681712), Swedish State Support for Clinical Research (#ALFGBG-720931), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), and the UK Dementia Research Institute at UCL. KB is supported by the Swedish Research Council (#2017-00915), the Alzheimer Drug Discovery Foundation (ADDF), USA (#RDAPB-201809-2016615), the Swedish Alzheimer Foundation (#AF-742881), Hjärnfonden, Sweden (#FO2017-0243), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986), and European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236).</funding-statement></funding-group><counts><fig-count count="3"/><table-count count="1"/><page-count count="14"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>Data are available upon request. Data contain sensitive information about patients status. We are prohibited from sharing the data publicly for general research that was not described in the consent procedure. Data are available upon request from researchers who have ethical approval from the Skåne University Hospital, Bild och Funktion, <email>forskningssamarbete.bf.sus@skane.se</email>. Further data access queries can be directed to Sophia Zackrisson, Skånes universitetssjukhus, Diarium, Rådhus Skåne, 291 89 Kristianstad, Sweden, e-mail address: <email>sophia.zackrisson@skane.se</email>, phone: +46 40 33 87 97</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>Data are available upon request. Data contain sensitive information about patients status. We are prohibited from sharing the data publicly for general research that was not described in the consent procedure. Data are available upon request from researchers who have ethical approval from the Skåne University Hospital, Bild och Funktion, <email>forskningssamarbete.bf.sus@skane.se</email>. Further data access queries can be directed to Sophia Zackrisson, Skånes universitetssjukhus, Diarium, Rådhus Skåne, 291 89 Kristianstad, Sweden, e-mail address: <email>sophia.zackrisson@skane.se</email>, phone: +46 40 33 87 97</p></notes></front><body><sec sec-type="intro" id="sec001"><title>Introduction</title><p>In the central nervous system, neurofilaments are cytoskeletal components of neurons that are particularly abundant in axons, where neurofilaments provide structural support and contribute maintaining size, shape, and caliber of the axons [<xref rid="pone.0236384.ref001" ref-type="bibr">1</xref>]. Neurofilament light chain (NfL) is the most abundant and soluble of the neurofilament subunits and can be reliably measured in cerebrospinal fluid (CSF) as well as in blood. The high correlation between CSF and blood concentrations of NfL (e.g., in plasma [<xref rid="pone.0236384.ref002" ref-type="bibr">2</xref>,<xref rid="pone.0236384.ref003" ref-type="bibr">3</xref>]) opened the avenue to the development of an accurate and noninvasive biomarker for diagnostics and, possibly, for monitoring the effect of disease modifying drugs during treatment trials. In recent years, NfL has rapidly emerged as one of the most promising fluid biomarkers in several neurodegenerative conditions including Alzheimer’s disease [<xref rid="pone.0236384.ref004" ref-type="bibr">4</xref>] and atypical parkinsonian disorders [<xref rid="pone.0236384.ref005" ref-type="bibr">5</xref>]. Early on a markedly increased CSF levels of NfL in frontotemporal dementia (FTD) as compared with controls and Alzheimer´s disease was found [<xref rid="pone.0236384.ref006" ref-type="bibr">6</xref>], a finding valid also for NfL in blood [<xref rid="pone.0236384.ref007" ref-type="bibr">7</xref>], and increased peripheral NfL has now been reliably validated in FTD [<xref rid="pone.0236384.ref008" ref-type="bibr">8</xref>–<xref rid="pone.0236384.ref013" ref-type="bibr">13</xref>]. A dramatic increase compared with controls and other neurodegenerative conditions has been also exhaustively documented in amyotrophic lateral sclerosis (ALS) [<xref rid="pone.0236384.ref014" ref-type="bibr">14</xref>–<xref rid="pone.0236384.ref016" ref-type="bibr">16</xref>].</p><p>NfL is mostly found in long, myelinated axons, and was found early to correlate with white matter changes (white matter is, together with myelin and glia, constituted by axons) [<xref rid="pone.0236384.ref017" ref-type="bibr">17</xref>], but only few studies have investigated the association between NfL and other in vivo markers that reflect the involvement of white matter in the neurodegenerative process [<xref rid="pone.0236384.ref012" ref-type="bibr">12</xref>,<xref rid="pone.0236384.ref018" ref-type="bibr">18</xref>]. In ALS, increased NfL concentration in both CSF and blood have been reported to correlate specifically with the degeneration of the cortico-spinal tract [<xref rid="pone.0236384.ref016" ref-type="bibr">16</xref>,<xref rid="pone.0236384.ref019" ref-type="bibr">19</xref>], while in FTD, both Steinacker and colleagues [<xref rid="pone.0236384.ref012" ref-type="bibr">12</xref>] and Sherling and colleagues [<xref rid="pone.0236384.ref018" ref-type="bibr">18</xref>], have shown an association between the serum concentration of NfL and decrease in frontal white matter volume. Understanding the link between peripheral NfL and aspects of the neurodegenerative process in FTD would be critical to guide the interpretation of NfL levels in the context of both clinical practice and treatment trials. To the best of our knowledge, no previous study has investigated the link between peripheral NfL level and the pathological changes in white matter occurring in FTD using diffusion tensor imaging (DTI) which is one of the most sensitive imaging techniques to capture such changes <italic toggle="yes">in vivo</italic>.</p><p>In the present study, we used DTI to explore the potential relationship between plasma NfL concentration and white matter degeneration in a group of patients affected by behavioral variant FTD (bvFTD). DTI has already proved to be able to reflect white matter degeneration profiles in FTD [<xref rid="pone.0236384.ref020" ref-type="bibr">20</xref>] and considering the results of previous studies, we aimed to test whether the peripheral concentration of NfL are associated with the degeneration of specific tracts, as appears to be the case in ALS, or if NfL reflects the general level of severity of white matter atrophy in bvFTD, as suggested by the previous studies [<xref rid="pone.0236384.ref012" ref-type="bibr">12</xref>,<xref rid="pone.0236384.ref018" ref-type="bibr">18</xref>]. To this end, the association between DTI metrics and NfL levels was investigated both unbiasedly at the whole-brain white matter level and in a region-of-interest analysis focusing on white matter tracts that are known to be involved in the bvFTD pathological process. Previous studies on FTD based on the quantification of DTI metrics [<xref rid="pone.0236384.ref020" ref-type="bibr">20</xref>–<xref rid="pone.0236384.ref022" ref-type="bibr">22</xref>] as well as on a combination of tensor based tractography and quantification of DTI metrics [<xref rid="pone.0236384.ref023" ref-type="bibr">23</xref>] have indeed showed extensive pattern of white matter involvement including the fronto-occipital fasciculus, the superior longitudinal fasciculus, the uncinate fasciculus, the dorsal cingulum bundle, the anterior thalamic radiation, and the inferior/hippocampal portion of the cingulum bundle. We also included in our analysis tracts in which degeneration has been reported to correlate with NfL level in previous DTI studies, in particular the cortico-spinal tract [<xref rid="pone.0236384.ref016" ref-type="bibr">16</xref>,<xref rid="pone.0236384.ref019" ref-type="bibr">19</xref>]. Moreover, we aimed to explore the potential association between NfL levels and cortical thickness to investigate the specificity of the hypothesized link between plasma NfL levels and white matter degeneration.</p></sec><sec sec-type="materials|methods" id="sec002"><title>Material and methods</title><sec id="sec003"><title>Participants</title><p>Twenty patients affected by the behavioral variant frontotemporal dementia (bvFTD) were included in the study. The participants took part in the Lund Prospective Frontotemporal Dementia Study (LUPROFS), a longitudinal study of patients with any of the frontotemporal dementia spectrum disorders which included patients from 2009 to 2014 at the Memory Clinic of Skåne University Hospital in Lund, Sweden. The LUPROFS protocol includes clinical examination, caregiver history, symptom rating, neuropsychological examination, standardized neurological examination and, at baseline, CSF and blood sample and MRI. bvFTD patients were diagnosed by a multidisciplinary team accordingly to the International Behavioral Variant FTD Consortium Criteria [<xref rid="pone.0236384.ref024" ref-type="bibr">24</xref>]. Genetic screening for mutations in the genes of microtubule-associated protein tau (MAPT), progranulin (GRN), and in chromosome 9 open reading frame 72 (C9ORF72) was performed in all patients. Postmortem neuropathological examination was aimed for in all patients deceased during follow up. The exclusion criteria included: &gt; 3 lacunar strokes or any number of other type of strokes visible on MRI examination, alcohol addiction, or any other significant neurological or psychiatric comorbidity. Patients were included in the present study only if they had a clinical diagnosis of probable or definite bvFTD, underwent MRI successfully with all relevant sequences to this study, and underwent MRI within a year from blood sampling. Twenty of the 41 subjects with bvFTD included in the LUPROFS cohort, could be included in the present study. No standardized assessment of motor functions was performed as part of the study, however, one patient had a diagnosis of FTD with motor neuron disease (FTD-MND, according to the Awji criteria [<xref rid="pone.0236384.ref025" ref-type="bibr">25</xref>]). More details on inclusion procedure and instruments can be found in [<xref rid="pone.0236384.ref023" ref-type="bibr">23</xref>]. 22 healthy controls were also included in the study for the purpose of building an unbiased white matter template (see the sction on the Diffusion tensor imaging (DTI) analysis). Healthy controls underwent the same protocol as the included patients. Demographic and clinical features of the cohort are presented in <xref rid="pone.0236384.t001" ref-type="table">Table 1</xref>. The study was approved by the Regional Ethical Review Board, Lund, Sweden (Number 617/2008). Patients and healthy controls were informed of the study content in both oral and written form. Informed consent was obtained in written form.</p><table-wrap id="pone.0236384.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0236384.t001</object-id><label>Table 1</label><caption><title>Demographic information.</title></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pone.0236384.t001g" position="float" orientation="portrait" xlink:href="pone.0236384.t001.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">bvFTD</th><th align="left" rowspan="1" colspan="1">Healthy controls</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Number (Female)</td><td align="left" rowspan="1" colspan="1">20 (10)</td><td align="left" rowspan="1" colspan="1">22 (11)</td></tr><tr><td align="left" rowspan="1" colspan="1">Diagnostic confidence<xref ref-type="table-fn" rid="t001fn003">*</xref></td><td align="left" rowspan="1" colspan="1">9 cases–definite<sup>+</sup> 11 cases–probable</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Age (std.)</td><td align="left" rowspan="1" colspan="1">68 (9)</td><td align="left" rowspan="1" colspan="1">65 (11)</td></tr><tr><td align="left" rowspan="1" colspan="1">MMSE (std.)</td><td align="left" rowspan="1" colspan="1">23.2 (4.9)</td><td align="left" rowspan="1" colspan="1">29.6 (0.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">Interval plasma–MRI in months (std; interval range in months)</td><td align="left" rowspan="1" colspan="1">0.2 (3.1; 0–10)</td><td align="left" rowspan="1" colspan="1">--</td></tr><tr><td align="left" rowspan="1" colspan="1">FTLD-CDR (std.)</td><td align="left" rowspan="1" colspan="1">1.7 (0.6)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">FTLD-CDR sum of boxes (std.)</td><td align="left" rowspan="1" colspan="1">8.7 (4.0)</td><td align="left" rowspan="1" colspan="1">--</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p>Values are given as mean and standard deviation (std).</p></fn><fn id="t001fn002"><p>Abbreviations: bvFTD: behavioural variant frontotemporal dementia; FTLD-CDR = frontotemporal lobar degeneration Clinical Dementia Rating; MMSE: Mini Mental State Examination.</p></fn><fn id="t001fn003"><p>*According to International Behavioral Variant FTD Consortium Criteria [<xref rid="pone.0236384.ref024" ref-type="bibr">24</xref>]. <sup>+</sup> 6 patients fulfill definite bvFTD criteria according to neuropathological examination, 2 according to genetic examination, and one according to both. Demographic factors and clinical characteristics were compared using Chi-square (x<sup>2</sup>) and Mann-Whitney U tests [Sex: x<sup>2</sup> = 0, p &gt; 0.9; Age: U = 155, p = 0.052; MMSE: U = 13.5, p &lt; 0.001].</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec004"><title>Imaging protocol</title><p>MRI was performed using a Philips Achieva 3T scanner equipped with an eight-channel head coil. Diffusion weighted imaging (DWI) was performed with an echo-planar single-shot spin echo sequence. Diffusion encoding was performed in 48 directions at a b-value of 800 s/mm<sup>2</sup> along with 1 volume with b-value of 0. The voxel size was 2×2×2 mm<sup>3</sup>, TR 7881 ms and TE 90 ms. A T1-weighted 3D volumetric sequence was also acquired with a voxel size of 1×1×1 mm<sup>3</sup>, TR 8.3 ms, TE 3.84 ms, FOV 256×256×175 mm<sup>3</sup>.</p></sec><sec id="sec005"><title>Plasma neurofilament light chain (NfL) protocol</title><p>Plasma NfL concentration was measured using an in house ultrasensitive enzyme-linked immunosorbent assay on a Single molecule array platform (Quanterix Corp, Billerica, MA, USA), as previously described [<xref rid="pone.0236384.ref026" ref-type="bibr">26</xref>]. All measurements were performed in one round of experiments, using one batch of reagents with intra-assay coefficients of variation below 10%.</p></sec><sec id="sec006"><title>Diffusion tensor imaging (DTI) analysis</title><p>The diffusion data were corrected for motion and eddy current induced artifacts using an extrapolation-based registration approach as previously reported [<xref rid="pone.0236384.ref027" ref-type="bibr">27</xref>]. A single diffusion tensor model was fitted to these data using FMRIB Software Library and parametric maps of fractional anisotropy (FA), mean diffusivity (MD), radial diffusivity (RD), and axial diffusivity (AD) were subsequently computed. Tract-based spatial statistics pipeline (TBSS, [<xref rid="pone.0236384.ref028" ref-type="bibr">28</xref>]) was then applied to the parametric maps. In brief, the FA maps were warped to the FMRIB58_FA standard template (FMRIB, University of Oxford, UK; resolution: 1×1×1mm<sup>3</sup>) in MNI152 space (Montreal Neurological Institute, McGill University, Canada) using FMRIB's non-linear registration tool (FNIRT v1.0). All the warped FA maps, including the maps of the healthy controls, were subsequently averaged to create a mean FA template, from which the FA skeleton was computed, imposing an FA threshold of 0.2. The FA maps of each participant were then, projected onto the skeleton as well as the other DTI scalars. In the present study we focus especially on a subset of tracts of interest, that consistently have been reported as affected in bvFTD in previous DTI studies [<xref rid="pone.0236384.ref020" ref-type="bibr">20</xref>,<xref rid="pone.0236384.ref021" ref-type="bibr">21</xref>,<xref rid="pone.0236384.ref023" ref-type="bibr">23</xref>] namely: the fronto-occipital fasciculus (FOF), the superior longitudinal fasciculus (SLF), the uncinate fasciculus (UF), cortico-spinal tract (CST), the dorsal cingulum bundle (dCin), the anterior thalamic radiation (ATR), and the inferior/hippocampal portion of the cingulum bundle (iCin). In order to extract summary metric from these tracts the Johns Hopkins University white-matter tractography atlas (available in FMRIB software library; FSL) [<xref rid="pone.0236384.ref029" ref-type="bibr">29</xref>] were intercepted with study-wise FA skeleton and the median values of FA, MD, RD and AD were extracted from each tract of interest for each participant.</p></sec><sec id="sec007"><title>Cortical thickness analysis</title><p>Cortical reconstruction and volumetric segmentation were performed on the T1-weighted 3D image using Freesurfer 5.3 image analysis pipeline which is documented and freely available for download online (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://surfer.nmr.mgh.harvard.edu/">http://surfer.nmr.mgh.harvard.edu/</ext-link>). The technical details of these procedures are described in prior publications, which are listed at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://surfer.nmr.mgh.harvard.edu/fswiki/FreeSurferMethodsCitation">https://surfer.nmr.mgh.harvard.edu/fswiki/FreeSurferMethodsCitation</ext-link>. Briefly, the whole-brain T1-weighted images underwent a correction for intensity homogeneity, skull striping, and segmentation into grey and white matter with intensity gradient and connectivity among voxels. Cortical thickness was measured as the distance from the gray/white matter boundary to the corresponding pial surface. Assessment of intracranial volume was also performed using Freesurfer. Reconstructed data sets were visually inspected for accuracy, and segmentation errors were corrected. Quality control of the Freesurfer output was performed by OL.</p></sec><sec id="sec008"><title>Statistical analysis</title><p>A set of whole-skeleton voxel-wise regression analyses on the DTI metrics was performed with the Randomize tool [<xref rid="pone.0236384.ref030" ref-type="bibr">30</xref>] version 2.9 available in FSL with 10000 permutations, threshold-free cluster enhancement [<xref rid="pone.0236384.ref031" ref-type="bibr">31</xref>] and 2D optimization for tract-based DTI analysis. NfL level was included as independent variable in each model along with age at scan as a nuissance covariate. Whole-skeleton statistical significance was set at the family-wise error corrected threshold of p&lt;0.05.</p><p>Potential differences between DTI metrics in the tracts of interest across hemisphere were assessed with Wilcoxon test. The association between DTI metrics and NfL was investigated employing multiple linear least square regression models and Benjamin Hochberg procedure for False Discovery Rate (FDR; p-value threshold = 0.05). Plasma NfL levels were log transformed and modeled as independent variable along with age as a nuisance covariate.</p><p>Cortical thickness analysis was performed using the QueryDesign Estimate Contrast (QDEC) tool. In parallel with the DTI analysis the model includes cortical thickness as dependent variable while plasma NfL levels were modeled as independent variable along with age at time of MRI scan as nuisance covariate. The results of the GLM analysis were corrected for multiple comparisons at the cluster level using the Monte Carlo simulation. The level of statistical significance was evaluated using a cluster-wise P (CWP) value correction procedure for multiple comparisons based on a Monte Carlo z-field simulation with a cluster forming vertex-z-threshold of 1.3 corresponding to p &lt; 0.05. All the analyses were performed using Python (3.7) except the voxel-wise analyses (as previously described).</p></sec></sec><sec sec-type="results" id="sec009"><title>Results</title><sec id="sec010"><title>Voxel-wise TBSS analysis</title><p>The voxel-wise regression analysis in patients affected by bvFTD revealed a negative correlation between plasma NfL levels and a widespread pattern of reduction in FA values which encompass the uncinate fasciculus bilaterally, the anterior thalamic radiation, the corpus callosum (genu, body and splenium), the inferior fronto-occipital fasciculus (more extensively on the right side) and the left corticospinal tract/cerebral peduncle (see <xref ref-type="fig" rid="pone.0236384.g001">Fig 1</xref>). No positive correlation between plasma NfL levels and FA was found and plasma NfL levels did not correlate with any other of the DTI metrics (MD, RD or AD) after correction for multiple comparisons.</p><fig id="pone.0236384.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0236384.g001</object-id><label>Fig 1</label><caption><title>Results of the voxel-wise TBSS analysis.</title><p>Highlighted clusters (in red) represent significant (family wise error, FWE &lt; 0.05) age corrected negative correlations between fractional anisotropy (FA) and plasma neurofilament light (NfL) protein levels among the patients with behavioural variant frontotemporal dementia (bvFTD). The average skeleton is displayed in green. The results were overlaid onto the study-specific mean FA map.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pone.0236384.g001.jpg"/></fig></sec><sec id="sec011"><title>Tracts of interest analysis</title><p>Considering that the voxel-wise analysis revealed significant results only for FA we focused the tract of interest analysis on this metric. The Wilcoxon test showed significant differences in FA values between the right and left side of some of the tracts of interest [FOF: W = 170, p&lt;0.001; dCin: W = 247, p&lt;0.05; SLF: W = 281, p&lt;0.05]. Therefore, further analysis was performed separately for the two hemispheres.</p><p>A negative correlation between FA and plasma NfL level was significant after correction for multiple comparisons (Bonferroni corrected alpha = 0.05/12) in several tracts of interests namely in the FOF [lFOF: β = -0.03, FDR-p&lt;0.05; rFOF: β = -0.03, FDR-p&lt;0.05], in the SLF [lSLF: β = -0.03, FDR-p&lt;0.05; rSLF: β = -0.03, FDR-p&lt;0.05], in the left UF [β = -0.03, FDR-p &lt; 0.05], in the right ATR [β = -0.04, FDR-p&lt;0.05] and in the right dCin [β = -0.04, FDR-p&lt;0.05]. The correlation between FA values and NfL in the left ATR, the right UF and in the left dCin was only marginally significant [lATR: β = -0.02, p = 0.06; rUF: β = -0.04, p = 0.06; ldCin: β = -0.03, p = 0.05]. No significant correlation was found in the CST [lCST–group: β = -0.01, p&gt;0.1; rCST–group: β = -0.01, p&gt;0.1] (see <xref ref-type="fig" rid="pone.0236384.g002">Fig 2</xref> and <xref ref-type="supplementary-material" rid="pone.0236384.s002">S2 Appendix</xref> for the complete statistical results). FA was significantly reduced in the bvFTD group relative to the healthy controls in all the tracts of interest except in the inferior cingulum bundle (see <xref ref-type="supplementary-material" rid="pone.0236384.s001">S1 Appendix</xref>).</p><fig id="pone.0236384.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0236384.g002</object-id><label>Fig 2</label><caption><title>Regional analysis of specific tracts.</title><p>Abbreviations: ATR: anterior thalamic radiation; CST: corticospinal tract; dCin: dorsal cingulum bundle; FA: fractional anisotropy; FOF: fronto-occipital fasciculus; iCin: inferior/hippocampal portion cingulum bundle; NfL: neurofilament light chain; SFL: superior longitudinal fasciculus; UF: uncinate fasciculus. Median FA values for each tract of interest plotted as a function of the log transformed plasma NfL levels among the patients with behavioral variant frontotemporal dementia bvFTD. The translucent area around the regression line represents the 95% confidential interval for the regression estimate.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pone.0236384.g002.jpg"/></fig></sec><sec id="sec012"><title>Cortical thickness analysis</title><p>Whole-brain regression analysis revealed a significant negative correlation between cortical thickness and plasma NfL level in the right medial prefrontal cortex and in the right lateral orbitofrontal cortex (see <xref ref-type="fig" rid="pone.0236384.g003">Fig 3</xref>).</p><fig id="pone.0236384.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0236384.g003</object-id><label>Fig 3</label><caption><title>Relationship between cortical thickness and plasma NfL levels.</title><p>Highlighted clusters represent significant (family-wise error, FWE &lt; 0.05) age corrected negative correlations between cortical thickness and plasma neurofilament light chain (NfL) levels among the patients with behavioral variant frontotemporal dementia (bvFTD).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pone.0236384.g003.jpg"/></fig></sec></sec><sec sec-type="conclusions" id="sec013"><title>Discussion</title><p>This study explored for the first time the association between plasma NfL levels and DTI metrics in a group of patients affected by bvFTD. We first took a voxel-wise approach to test the extent of the association between DTI metrics and NfL across all white matter structures and then we focused specifically on a subset of tracts of interest, that consistently have been reported to be affected in previous DTI studies on bvFTD [<xref rid="pone.0236384.ref020" ref-type="bibr">20</xref>–<xref rid="pone.0236384.ref022" ref-type="bibr">22</xref>]. The voxel-wise analysis revealed a pattern of negative association between FA and plasma NfL levels that was consistent with the spatial distribution of white matter degeneration in bvFTD as assessed by neuropathology [<xref rid="pone.0236384.ref032" ref-type="bibr">32</xref>] and previous DTI studies [<xref rid="pone.0236384.ref020" ref-type="bibr">20</xref>–<xref rid="pone.0236384.ref022" ref-type="bibr">22</xref>]. The analysis of specific tracts of interest also showed a negative correlation between plasma NfL levels and FA, in all the tracts under examination with the only exception of the cortico-spinal tract. These results suggested a strong link between white matter involvement in bvFTD and the increase of plasma NfL level, providing further evidence of the link between peripheral NfL concentration and the central pathological process in bvFTD.</p><p>NfL is the most promising fluid biomarker for diagnostics and monitoring degeneration in FTD both in the context of clinical practice as well as in clinical trials [<xref rid="pone.0236384.ref033" ref-type="bibr">33</xref>] In the diagnostic process, NfL is the only fluid biomarker with potential to separate bvFTD from psychiatric disorders [<xref rid="pone.0236384.ref034" ref-type="bibr">34</xref>,<xref rid="pone.0236384.ref035" ref-type="bibr">35</xref>], which constitute the main differential diagnosis for bvFTD [<xref rid="pone.0236384.ref036" ref-type="bibr">36</xref>]. Plasma is arguably preferable to CSF for NfL measurements due to the minimally invasive procedure required to sample it. Considering the potential value of this marker, it is relevant to clarify what aspect of the FTD pathological process is reflected by NfL levels. The present results point to a clear link between white matter degeneration (and presumably neuronal axons, its main constituent together with myelin and glia) and NfL (presumably mainly emanating from neuronal axons) levels in plasma. Both CSF and blood concentrations of NfL have been previously associated with <italic toggle="yes">grey</italic> matter atrophy in several neurodegenerative diseases, including FTD. For example, van der Ende and colleagues have recently reported that the rate of changes in serum NfL concentration in genetic FTD cases was correlated with rate of volume reduction in several cortical and subcortical regions including frontal lobe, insula, cingulate gyrus, hippocampus, putamen, temporal lobe and amygdala [<xref rid="pone.0236384.ref037" ref-type="bibr">37</xref>]. Similarly, Meeter et al. have shown a negative association between NfL levels in the CSF and parahippocampal volume in a large cross-sectional study on the semantic variant of primary progressive aphasia [<xref rid="pone.0236384.ref009" ref-type="bibr">9</xref>]. However, these studies did not assess the association between NfL and white matter involvement. Both Scherling and colleagues and Steinacker and colleagues have, instead, reported negative correlation between CSF concentration of NfL and both gray and white matter volume across different phenotypes of FTD [<xref rid="pone.0236384.ref018" ref-type="bibr">18</xref>]. The present study using DTI metrics indicate a spatially more diffuse relationship between NfL and white matter, compared to the association between NfL levels and white matter volume. Although, a direct comparison between studies employing alternative techniques is not possible, the difference could be due to the superior sensitivity of DTI in detecting pathological processes in white matter. Although NfL are structural components of axons, they are also present in gray matter; therefore, gray matter degeneration could contribute to the increase of peripheral NfL concentration. In Alzheimer’s disease, plasma NfL levels have been shown to correlate both cross-sectionally and longitudinally with cortical thinning in regions typically affected by the Alzheimer neurodegenerative process, such as entorhinal, inferior temporal, middle temporal, and fusiform cortex [<xref rid="pone.0236384.ref004" ref-type="bibr">4</xref>]. In the present study, plasma NfL levels were also associated with cortical thinning in a portion of the right medial prefrontal cortex and the right lateral orbitofrontal cortex. These regions constitute a subset of the prefrontal, insular and temporal cortex typically affected by atrophy in bvFTD [<xref rid="pone.0236384.ref038" ref-type="bibr">38</xref>]. The extent of the association between NfL and cortical thinning appears to be relatively modest compared to the widespread pattern of associations with FA. Such a difference could be related to the biology of NfL, which are particularly abundant in highly myelinated axons, but the difference in statistical results could also be due to lack of power for detecting statistical associations with a morphometric analysis.</p><p>In the present study we tested whether bvFTD plasma NfL levels are associated with a particular spatial profile of white matter involvement, where several scenarios could be hypothesized. In ALS, an increase in the peripheral concentration of NfL levels has been associated with changes in diffusion metrics mostly in the cortico-spinal tracts [<xref rid="pone.0236384.ref014" ref-type="bibr">14</xref>–<xref rid="pone.0236384.ref016" ref-type="bibr">16</xref>]. Thus, given the close relationship between ALS and FTD, a subclinical corticospinal tract involvement could drive the increased NfL levels in FTD. Analogously, a semantic dementia (i.e. semantic variant of primary progressive aphasia) like pattern, with NfL correlations with the uncinate fasciculus mainly, could be expected given that semantic dementia shows higher NfL levels than other primary progressive aphasias and has a characteristic involvement of the uncinate fasciculus [<xref rid="pone.0236384.ref009" ref-type="bibr">9</xref>]. A specific association with the uncinate fasciculus could also be expected given that this is one of the earliest tracts affected in bvFTD [<xref rid="pone.0236384.ref039" ref-type="bibr">39</xref>] and increased NfL seem to be an early event in FTD [<xref rid="pone.0236384.ref037" ref-type="bibr">37</xref>]. Both the voxel-wise results and the regional analysis seems to point, instead, to a diffuse association of NfL with FA in the main tracts that are involved in the neurodegenerative process of bvFTD. The association appeared to be prominent in the majority of tracts studied, which all are long interlobar tracts with diverse functions (i.e. association, commissural, and projection tracts), with the notable exception of the CST. The results in the CST appear counter intuitive given what is reported above on regarding ALS. However, there are inconsistencies and the largest study of ALS to date has indeed not shown correlation between NfL and DTI metrics [<xref rid="pone.0236384.ref040" ref-type="bibr">40</xref>].</p><p>The association between plasma NfL levels and FA values in the majority of tracts affected by the disease process is in line with both cross-sectional and longitudinal studies in the FTD spectrum showing that levels of NfL are increased with disease severity and associated with poorer prognosis [<xref rid="pone.0236384.ref007" ref-type="bibr">7</xref>,<xref rid="pone.0236384.ref010" ref-type="bibr">10</xref>,<xref rid="pone.0236384.ref011" ref-type="bibr">11</xref>,<xref rid="pone.0236384.ref018" ref-type="bibr">18</xref>,<xref rid="pone.0236384.ref037" ref-type="bibr">37</xref>,<xref rid="pone.0236384.ref041" ref-type="bibr">41</xref>]. Although it is not the primary outcome of the present study, the association between NfL levels and disease severity holds also in our cohort has revealed by a positive association between NfL and FTLD-CDR sum of boxes [Spearman’s rho = 0.7; p &lt; 0.001]. Of particular interest is that both Meeter and colleagues [<xref rid="pone.0236384.ref011" ref-type="bibr">11</xref>] and van der Ende and colleagues [<xref rid="pone.0236384.ref037" ref-type="bibr">37</xref>] showed that in genetic FTD cases, the serum concentration of NfL is clearly higher in symptomatic versus asymptomatic mutation carriers. We believe the current finding further strengthen the validity of NfL as a biomarker of disease severity and thus potentially as a surrogate outcome measure in treatment trials. What emerges as a caveat from this, and previous studies, is that the association with disease severity could mean that NfL is less useful in patients that not yet have a full clinical bvFTD dementia (i.e. prodromal bvFTD, or bvFTD at the mild cognitive impairment level), which would limit its application in the psychiatric differential diagnostic setting.</p><p>In addition to the relatively small sample size, other limitations should be taken into account while evaluating the results of the present study. bvFTD is a clinical phenotype, and, currently there is no in vivo marker that can disentangle the underlying pathology, namely tauopathy or TAR DNA-binding protein 43 (TDP-43) proteinopathy. Evidence of increased NfL levels in ALS/MND, which is most commonly a TDP-43 proteinopathy [<xref rid="pone.0236384.ref042" ref-type="bibr">42</xref>–<xref rid="pone.0236384.ref044" ref-type="bibr">44</xref>], and in the semantic variant primary progressive aphasia [<xref rid="pone.0236384.ref009" ref-type="bibr">9</xref>,<xref rid="pone.0236384.ref010" ref-type="bibr">10</xref>], which also most commonly characterized by misfolding of TDP-43 [<xref rid="pone.0236384.ref045" ref-type="bibr">45</xref>], suggest a link between NfL and TDP-43 proteinopathy in the FTD spectrum [<xref rid="pone.0236384.ref010" ref-type="bibr">10</xref>]. However, other studies have shown that NfL levels are elevated in primary tauopathies like progressive supranuclear palsy [<xref rid="pone.0236384.ref005" ref-type="bibr">5</xref>]. Although, the purpose of our study was the investigation of the association between plasma NfL levels and DTI metric in a clinical phenotype (bvFTD), the potential confounding effect of mixed underlying proteinopathies must be taken into consideration. Increased peripheral NfL has now been reliably validated in FTD [<xref rid="pone.0236384.ref008" ref-type="bibr">8</xref>–<xref rid="pone.0236384.ref013" ref-type="bibr">13</xref>] and was not a purpose of the current study; however the lack of a direct comparison of plasma NfL levels between bvFTD and healthy controls is also a limitation of the present study. Moreover, the lack of association between plasma NfL levels and DTI metrics other than FA in the TBSS analysis is surprising when considering the extent of the association between NfL levels and FA values. A follow up study in a bigger cohort is warranted to investigate whether, with greater statistical power, associations with other metrics would emerge. Different DTI metrics could also be differently sensitive to different biological process. For example, FA appears to distinguish between progressive supranuclear palsy and Parkinson’s disease with higher level of accuracy than other DTI metrics [<xref rid="pone.0236384.ref046" ref-type="bibr">46</xref>], while axial and mean diffusivity seem to be the first DTI-related abnormalities to occur in Alzheimer’s disease [<xref rid="pone.0236384.ref047" ref-type="bibr">47</xref>]. However, one should bear in mind that, although DTI metrics are sensitive to pathological processes in white matter, they cannot be interpreted as a direct proxy of a specific biological process like axonal degeneration, which is the likely cause of the increased peripheral levels of NfL. A measure such as FA is, indeed, sensitive both to anisotropy, which is caused by the presence of elongated cell structures, like axons, and orientation dispersion, which is caused by fanning or crossing fibers [<xref rid="pone.0236384.ref048" ref-type="bibr">48</xref>]. Therefore, DTI cannot pinpoint the biological bases of a reduction in FA nor reflect the complexity of white matter organization. Alternative acquisition strategies have been proposed [<xref rid="pone.0236384.ref048" ref-type="bibr">48</xref>–<xref rid="pone.0236384.ref050" ref-type="bibr">50</xref>] but the estimation of an exact biologic property remains challenging despite the use of both advanced DWI sequences and modeling [<xref rid="pone.0236384.ref051" ref-type="bibr">51</xref>].</p><p>With these caveats in mind, the present study provides in vivo evidence of a relationship between plasma NfL levels and involvement of white matter tracts in bvFTD pathophysiology. These results advance our understanding of the link between one of the most promising fluid biomarker of neurodegeneration in FTD and the pathological process occurring in this condition and further support the application of blood-derived NfL concentration as a noninvasive biomarker for application in a clinical setting and in treatment trials.</p></sec><sec sec-type="supplementary-material" id="sec014"><title>Supporting information</title><supplementary-material content-type="local-data" id="pone.0236384.s001" position="float" orientation="portrait"><label>S1 Appendix</label><caption><title>Tracts of interest analysis: Comparison of FA values between bvFTD and healthy controls.</title><p>(DOCX)</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pone.0236384.s001.docx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0236384.s002" position="float" orientation="portrait"><label>S2 Appendix</label><caption><title>Tracts of interest analysis: Association between FA and plasma NfL levels in the tracts that exhibited a reduction in FA in the bvFTD cohort.</title><p>(DOCX)</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pone.0236384.s002.docx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>We would like to thank both the patients and their relative who took part to the study. Without their dedication this work would have not been possible We would also like to thank the staff of the Memory Clinics at Skåne University Hospital. The LUPROFS study on which the present work is based on was initiated 2008 by the authors CN, DvW, MLW, AS, KN, SV and EE.</p></ack><ref-list><title>References</title><ref id="pone.0236384.ref001"><label>1</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Liem</surname><given-names>RKH</given-names></name>, <name name-style="western"><surname>Cleveland</surname><given-names>DW</given-names></name> (<year>1996</year>) <article-title>Neuronal Intermediate Filaments</article-title>. <source>Annu Rev Neurosci</source><volume>19</volume>:<fpage>187</fpage>–<lpage>217</lpage>. <pub-id pub-id-type="doi">10.1146/annurev.ne.19.030196.001155</pub-id><pub-id pub-id-type="pmid">8833441</pub-id></mixed-citation></ref><ref id="pone.0236384.ref002"><label>2</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Mattsson</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Andreasson</surname><given-names>U</given-names></name>, <name name-style="western"><surname>Zetterberg</surname><given-names>H</given-names></name>, <etal>et al</etal> (<year>2017</year>) <article-title>Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease</article-title>. <source>JAMA Neurol</source><volume>74</volume>:<fpage>557</fpage>–<lpage>566</lpage>. <pub-id pub-id-type="doi">10.1001/jamaneurol.2016.6117</pub-id><pub-id pub-id-type="pmid">28346578</pub-id><pub-id pub-id-type="pmcid">PMC5822204</pub-id></mixed-citation></ref><ref id="pone.0236384.ref003"><label>3</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Lu</surname><given-names>CH</given-names></name>, <name name-style="western"><surname>Macdonald-Wallis</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Gray</surname><given-names>E</given-names></name>, <etal>et al</etal> (<year>2015</year>) <article-title>Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis</article-title>. <source>Neurology</source><volume>84</volume>:<fpage>2247</fpage>–<lpage>2257</lpage>. <pub-id pub-id-type="doi">10.1212/WNL.0000000000001642</pub-id><pub-id pub-id-type="pmid">25934855</pub-id><pub-id pub-id-type="pmcid">PMC4456658</pub-id></mixed-citation></ref><ref id="pone.0236384.ref004"><label>4</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Mattsson</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Cullen</surname><given-names>NC</given-names></name>, <name name-style="western"><surname>Andreasson</surname><given-names>U</given-names></name>, <name name-style="western"><surname>Zetterberg</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Blennow</surname><given-names>K</given-names></name> (<year>2019</year>) <article-title>Association between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients with Alzheimer Disease</article-title>. <source>JAMA Neurol</source><volume>76</volume>:<fpage>791</fpage>–<lpage>799</lpage>. <pub-id pub-id-type="doi">10.1001/jamaneurol.2019.0765</pub-id><pub-id pub-id-type="pmid">31009028</pub-id><pub-id pub-id-type="pmcid">PMC6583067</pub-id></mixed-citation></ref><ref id="pone.0236384.ref005"><label>5</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Hansson</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Janelidze</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Hall</surname><given-names>S</given-names></name>, <etal>et al</etal> (<year>2017</year>) <article-title>Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder</article-title>. <source>Neurology</source><volume>88</volume>:<fpage>930</fpage>–<lpage>937</lpage>. <pub-id pub-id-type="doi">10.1212/WNL.0000000000003680</pub-id><pub-id pub-id-type="pmid">28179466</pub-id><pub-id pub-id-type="pmcid">PMC5333515</pub-id></mixed-citation></ref><ref id="pone.0236384.ref006"><label>6</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Sjögren</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Rosengren</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Minthon</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Davidsson</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Blennow</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Wallin</surname><given-names>A</given-names></name> (<year>2000</year>) <article-title>Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD</article-title>. <source>Neurology</source><volume>54</volume>:<fpage>1960</fpage>–<lpage>1964</lpage>. <pub-id pub-id-type="doi">10.1212/wnl.54.10.1960</pub-id><pub-id pub-id-type="pmid">10822437</pub-id></mixed-citation></ref><ref id="pone.0236384.ref007"><label>7</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Rohrer</surname><given-names>JD</given-names></name>, <name name-style="western"><surname>Woollacott</surname><given-names>IOC</given-names></name>, <name name-style="western"><surname>Dick</surname><given-names>KM</given-names></name>, <etal>et al</etal> (<year>2016</year>) <article-title>Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia</article-title>. <source>Neurology</source><volume>87</volume>:<fpage>1329</fpage>–<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1212/WNL.0000000000003154</pub-id><pub-id pub-id-type="pmid">27581216</pub-id><pub-id pub-id-type="pmcid">PMC5047041</pub-id></mixed-citation></ref><ref id="pone.0236384.ref008"><label>8</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Olsson</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Portelius</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Cullen</surname><given-names>NC</given-names></name>, <etal>et al</etal> (<year>2019</year>) <article-title>Association of Cerebrospinal Fluid Neurofilament Light Protein Levels with Cognition in Patients with Dementia, Motor Neuron Disease, and Movement Disorders</article-title>. <source>JAMA Neurol</source><volume>76</volume>:<fpage>318</fpage>–<lpage>325</lpage>. <pub-id pub-id-type="doi">10.1001/jamaneurol.2018.3746</pub-id><pub-id pub-id-type="pmid">30508027</pub-id><pub-id pub-id-type="pmcid">PMC6440232</pub-id></mixed-citation></ref><ref id="pone.0236384.ref009"><label>9</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Meeter</surname><given-names>LHH</given-names></name>, <name name-style="western"><surname>Steketee</surname><given-names>RME</given-names></name>, <name name-style="western"><surname>Salkovic</surname><given-names>D</given-names></name>, <etal>et al</etal> (<year>2019</year>) <article-title>Clinical value of cerebrospinal fluid neurofilament light chain in semantic dementia</article-title>. <source>J Neurol Neurosurg Psychiatry</source><volume>90</volume>:<fpage>997</fpage>–<lpage>1004</lpage>. <pub-id pub-id-type="doi">10.1136/jnnp-2018-319784</pub-id><pub-id pub-id-type="pmid">31123142</pub-id><pub-id pub-id-type="pmcid">PMC6820157</pub-id></mixed-citation></ref><ref id="pone.0236384.ref010"><label>10</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Landqvist Waldö</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Frizell Santillo</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Passant</surname><given-names>U</given-names></name>, <name name-style="western"><surname>Zetterberg</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Rosengren</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Nilsson</surname><given-names>C</given-names></name>, <etal>et al</etal> (<year>2013</year>) <article-title>Cerebrospinal fluid neurofilament light chain protein levels in subtypes of frontotemporal dementia</article-title>. <source>BMC Neurol</source><volume>13</volume>:<fpage>54</fpage><pub-id pub-id-type="doi">10.1186/1471-2377-13-54</pub-id><pub-id pub-id-type="pmid">23718879</pub-id><pub-id pub-id-type="pmcid">PMC3671150</pub-id></mixed-citation></ref><ref id="pone.0236384.ref011"><label>11</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Meeter</surname><given-names>LH</given-names></name>, <name name-style="western"><surname>Dopper</surname><given-names>EG</given-names></name>, <name name-style="western"><surname>Jiskoot</surname><given-names>LC</given-names></name>, <etal>et al</etal> (<year>2016</year>) <article-title>Neurofilament light chain: a biomarker for genetic frontotemporal dementia</article-title>. <source>Ann Clin Transl Neurol</source><volume>3</volume>:<fpage>623</fpage>–<lpage>636</lpage>. <pub-id pub-id-type="doi">10.1002/acn3.325</pub-id><pub-id pub-id-type="pmid">27606344</pub-id><pub-id pub-id-type="pmcid">PMC4999594</pub-id></mixed-citation></ref><ref id="pone.0236384.ref012"><label>12</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Steinacker</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Anderl-Straub</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Diehl-Schmid</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>2018</year>) <article-title>Serum neurofilament light chain in behavioral variant frontotemporal dementia</article-title>. <source>Neurology</source><volume>91</volume>:<fpage>E1390</fpage>–<lpage>E1401</lpage>. <pub-id pub-id-type="doi">10.1212/WNL.0000000000006318</pub-id><pub-id pub-id-type="pmid">30209235</pub-id></mixed-citation></ref><ref id="pone.0236384.ref013"><label>13</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Bridel</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Van Wieringen</surname><given-names>WN</given-names></name>, <name name-style="western"><surname>Zetterberg</surname><given-names>H</given-names></name>, <etal>et al</etal> (<year>2019</year>) <article-title>Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis</article-title>. <source>JAMA Neurol</source><volume>76</volume>:<fpage>1035</fpage>–<lpage>1048</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2019.1534</pub-id><pub-id pub-id-type="pmcid">PMC6580449</pub-id><pub-id pub-id-type="pmid">31206160</pub-id></mixed-citation></ref><ref id="pone.0236384.ref014"><label>14</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Poesen</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Van Damme</surname><given-names>P</given-names></name> (<year>2019</year>) <article-title>Diagnostic and prognostic performance of neurofilaments in ALS</article-title>. <source>Front Neurol</source>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fneur.2018.01167</pub-id><pub-id pub-id-type="pmcid">PMC6345692</pub-id><pub-id pub-id-type="pmid">30713520</pub-id></mixed-citation></ref><ref id="pone.0236384.ref015"><label>15</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Gaiani</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Martinelli</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Bello</surname><given-names>L</given-names></name>, <etal>et al</etal> (<year>2017</year>) <article-title>Diagnostic and prognostic biomarkers in amyotrophic lateral sclerosis: Neurofilament light chain levels in definite subtypes of disease</article-title>. <source>JAMA Neurol</source><volume>74</volume>:<fpage>525</fpage>–<lpage>532</lpage>. <pub-id pub-id-type="doi">10.1001/jamaneurol.2016.5398</pub-id><pub-id pub-id-type="pmid">28264096</pub-id><pub-id pub-id-type="pmcid">PMC5822207</pub-id></mixed-citation></ref><ref id="pone.0236384.ref016"><label>16</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Menke</surname><given-names>RAL</given-names></name>, <name name-style="western"><surname>Gray</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Lu</surname><given-names>CH</given-names></name>, <name name-style="western"><surname>Kuhle</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Talbot</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Malaspina</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2015</year>) <article-title>CSF neurofilament light chain reflects corticospinal tract degeneration in ALS</article-title>. <source>Ann Clin Transl Neurol</source><volume>2</volume>:<fpage>748</fpage>–<lpage>755</lpage>. <pub-id pub-id-type="doi">10.1002/acn3.212</pub-id><pub-id pub-id-type="pmid">26273687</pub-id><pub-id pub-id-type="pmcid">PMC4531057</pub-id></mixed-citation></ref><ref id="pone.0236384.ref017"><label>17</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Sjögren</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Blomberg</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Jonsson</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Wahlund</surname><given-names>LO</given-names></name>, <name name-style="western"><surname>Lind</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Rosengren</surname><given-names>L</given-names></name>, <etal>et al</etal> (<year>2001</year>) <article-title>Neurofilament protein in cerebrospinal fluid: A marker of white matter changes</article-title>. <source>J Neurosci Res</source><volume>66</volume>:<fpage>510</fpage>–<lpage>516</lpage>. <pub-id pub-id-type="doi">10.1002/jnr.1242</pub-id><pub-id pub-id-type="pmid">11746370</pub-id></mixed-citation></ref><ref id="pone.0236384.ref018"><label>18</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Scherling</surname><given-names>CS</given-names></name>, <name name-style="western"><surname>Hall</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Berisha</surname><given-names>F</given-names></name>, <etal>et al</etal> (<year>2014</year>) <article-title>Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration</article-title>. <source>Ann Neurol</source><volume>75</volume>:<fpage>116</fpage>–<lpage>126</lpage>. <pub-id pub-id-type="doi">10.1002/ana.24052</pub-id><pub-id pub-id-type="pmid">24242746</pub-id><pub-id pub-id-type="pmcid">PMC4020786</pub-id></mixed-citation></ref><ref id="pone.0236384.ref019"><label>19</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Schreiber</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Spotorno</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Schreiber</surname><given-names>F</given-names></name>, <etal>et al</etal> (<year>2018</year>) <article-title>Significance of CSF NfL and tau in ALS</article-title>. <source>J Neurol</source><volume>265</volume>:<fpage>2633</fpage>–<lpage>2645</lpage>. <pub-id pub-id-type="doi">10.1007/s00415-018-9043-0</pub-id><pub-id pub-id-type="pmid">30187162</pub-id></mixed-citation></ref><ref id="pone.0236384.ref020"><label>20</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Mahoney</surname><given-names>CJ</given-names></name>, <name name-style="western"><surname>Ridgway</surname><given-names>GR</given-names></name>, <name name-style="western"><surname>Malone</surname><given-names>IB</given-names></name>, <etal>et al</etal> (<year>2014</year>) <article-title>Profiles of white matter tract pathology in frontotemporal dementia</article-title>. <source>Hum Brain Mapp</source><volume>35</volume>:<fpage>4163</fpage>–<lpage>4179</lpage>. <pub-id pub-id-type="doi">10.1002/hbm.22468</pub-id><pub-id pub-id-type="pmid">24510641</pub-id><pub-id pub-id-type="pmcid">PMC4312919</pub-id></mixed-citation></ref><ref id="pone.0236384.ref021"><label>21</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Lam</surname><given-names>BYK</given-names></name>, <name name-style="western"><surname>Halliday</surname><given-names>GM</given-names></name>, <name name-style="western"><surname>Irish</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Hodges</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Piguet</surname><given-names>O</given-names></name> (<year>2014</year>) <article-title>Longitudinal white matter changes in frontotemporal dementia subtypes</article-title>. <source>Hum Brain Mapp</source><volume>35</volume>:<fpage>3547</fpage>–<lpage>3557</lpage>. <pub-id pub-id-type="doi">10.1002/hbm.22420</pub-id><pub-id pub-id-type="pmid">25050433</pub-id><pub-id pub-id-type="pmcid">PMC6869363</pub-id></mixed-citation></ref><ref id="pone.0236384.ref022"><label>22</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Santillo</surname><given-names>AF</given-names></name>, <name name-style="western"><surname>Lundblad</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Nilsson</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Waldö</surname><given-names>ML</given-names></name>, <name name-style="western"><surname>Van Westen</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Lätt</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>2016</year>) <article-title>Grey and white matter clinico-anatomical correlates of disinhibition in neurodegenerative disease</article-title>. <source>PLoS One</source><volume>11</volume>:<fpage>1</fpage>–<lpage>19</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0164122</pub-id><pub-id pub-id-type="pmcid">PMC5056728</pub-id><pub-id pub-id-type="pmid">27723823</pub-id></mixed-citation></ref><ref id="pone.0236384.ref023"><label>23</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Santillo</surname><given-names>AF</given-names></name>, <name name-style="western"><surname>Mårtensson</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Lindberg</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Nilsson</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Manzouri</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Landqvist Waldö</surname><given-names>M</given-names></name>, <etal>et al</etal> (<year>2013</year>) <article-title>Diffusion Tensor Tractography versus Volumetric Imaging in the Diagnosis of Behavioral Variant Frontotemporal Dementia</article-title>. <source>PLoS One</source><volume>8</volume>:<fpage>1</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0066932</pub-id><pub-id pub-id-type="pmcid">PMC3715470</pub-id><pub-id pub-id-type="pmid">23874403</pub-id></mixed-citation></ref><ref id="pone.0236384.ref024"><label>24</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Rascovsky</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Hodges</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Knopman</surname><given-names>D</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia</article-title>. <source>Brain</source><volume>134</volume>:<fpage>2456</fpage>–<lpage>2477</lpage>. <pub-id pub-id-type="doi">10.1093/brain/awr179</pub-id><pub-id pub-id-type="pmid">21810890</pub-id><pub-id pub-id-type="pmcid">PMC3170532</pub-id></mixed-citation></ref><ref id="pone.0236384.ref025"><label>25</label><mixed-citation publication-type="journal"><name name-style="western"><surname>de Carvalho</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Dengler</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Eisen</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Electrodiagnostic criteria for diagnosis of ALS</article-title>. <source>Clin Neurophysiol</source><volume>119</volume>:<fpage>497</fpage>–<lpage>503</lpage>. <pub-id pub-id-type="doi">10.1016/j.clinph.2007.09.143</pub-id><pub-id pub-id-type="pmid">18164242</pub-id></mixed-citation></ref><ref id="pone.0236384.ref026"><label>26</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Gisslén</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Price</surname><given-names>RW</given-names></name>, <name name-style="western"><surname>Andreasson</surname><given-names>U</given-names></name>, <name name-style="western"><surname>Norgren</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Nilsson</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Hagberg</surname><given-names>L</given-names></name>, <etal>et al</etal> (<year>2016</year>) <article-title>Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study</article-title>. <source>EBioMedicine</source><volume>3</volume>:<fpage>135</fpage>–<lpage>140</lpage>. <pub-id pub-id-type="doi">10.1016/j.ebiom.2015.11.036</pub-id><pub-id pub-id-type="pmid">26870824</pub-id><pub-id pub-id-type="pmcid">PMC4739412</pub-id></mixed-citation></ref><ref id="pone.0236384.ref027"><label>27</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Nilsson</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Szczepankiewicz</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Van Westen</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Hansson</surname><given-names>O</given-names></name> (<year>2015</year>) <article-title>Extrapolation-based references improve motion and eddy-current correction of high B-value DWI data: Application in Parkinson’s disease dementia</article-title>. <source>PLoS One</source>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0141825</pub-id><pub-id pub-id-type="pmcid">PMC4631453</pub-id><pub-id pub-id-type="pmid">26528541</pub-id></mixed-citation></ref><ref id="pone.0236384.ref028"><label>28</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Smith</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Jenkinson</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Johansen-Berg</surname><given-names>H</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>Tract-based spatial statistics: Voxelwise analysis of multi-subject diffusion data</article-title>. <source>Neuroimage</source><volume>31</volume>:<fpage>1487</fpage>–<lpage>1505</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroimage.2006.02.024</pub-id><pub-id pub-id-type="pmid">16624579</pub-id></mixed-citation></ref><ref id="pone.0236384.ref029"><label>29</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Hua</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Wakana</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Jiang</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Reich</surname><given-names>DS</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Tract probability maps in stereotaxic spaces: Analyses of white matter anatomy and tract-specific quantification</article-title>. <source>Neuroimage</source><volume>39</volume>:<fpage>336</fpage>–<lpage>347</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroimage.2007.07.053</pub-id><pub-id pub-id-type="pmid">17931890</pub-id><pub-id pub-id-type="pmcid">PMC2724595</pub-id></mixed-citation></ref><ref id="pone.0236384.ref030"><label>30</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Winkler</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Ridgway</surname><given-names>GR</given-names></name>, <name name-style="western"><surname>Webster</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Smith</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Nichols</surname><given-names>TE</given-names></name> (<year>2014</year>) <article-title>Permutation inference for the general linear model</article-title>. <source>Neuroimage</source><volume>92</volume>:<fpage>381</fpage>–<lpage>397</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroimage.2014.01.060</pub-id><pub-id pub-id-type="pmid">24530839</pub-id><pub-id pub-id-type="pmcid">PMC4010955</pub-id></mixed-citation></ref><ref id="pone.0236384.ref031"><label>31</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Smith</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Nichols</surname><given-names>TE</given-names></name> (<year>2009</year>) <article-title>Threshold-free cluster enhancement: Addressing problems of smoothing, threshold dependence and localisation in cluster inference</article-title>. <source>Neuroimage</source><volume>44</volume>:<fpage>83</fpage>–<lpage>98</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroimage.2008.03.061</pub-id><pub-id pub-id-type="pmid">18501637</pub-id></mixed-citation></ref><ref id="pone.0236384.ref032"><label>32</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Englund</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Brun</surname><given-names>A</given-names></name> (<year>1987</year>) <article-title>Frontal lobe degeneration of non-Alzheimer type IV. White matter changes</article-title>. <source>Arch Gerontol Geriatr</source><volume>6</volume>:<fpage>235</fpage>–<lpage>243</lpage>. <pub-id pub-id-type="doi">10.1016/0167-4943(87)90024-0</pub-id><pub-id pub-id-type="pmid">3689056</pub-id></mixed-citation></ref><ref id="pone.0236384.ref033"><label>33</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Meeter</surname><given-names>LH</given-names></name>, <name name-style="western"><surname>Kaat</surname><given-names>LD</given-names></name>, <name name-style="western"><surname>Rohrer</surname><given-names>JD</given-names></name>, <name name-style="western"><surname>Van Swieten</surname><given-names>JC</given-names></name> (<year>2017</year>) <article-title>Imaging and fluid biomarkers in frontotemporal dementia</article-title>. <source>Nat Rev Neurol</source><volume>13</volume>:<fpage>406</fpage>–<lpage>419</lpage>. <pub-id pub-id-type="doi">10.1038/nrneurol.2017.75</pub-id><pub-id pub-id-type="pmid">28621768</pub-id></mixed-citation></ref><ref id="pone.0236384.ref034"><label>34</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Eratne</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Loi</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Walia</surname><given-names>N</given-names></name>, <etal>et al</etal> (<year>2020</year>) <article-title>A pilot study of the utility of cerebrospinal fluid neurofilament light chain in differentiating neurodegenerative from psychiatric disorders: A ‘C-reactive protein’ for psychiatrists and neurologists?</article-title><source>Aust N Z J Psychiatry</source><volume>54</volume>:<fpage>57</fpage>–<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1177/0004867419857811</pub-id><pub-id pub-id-type="pmid">31220922</pub-id></mixed-citation></ref><ref id="pone.0236384.ref035"><label>35</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Katisko</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Cajanus</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Jääskeläinen</surname><given-names>O</given-names></name>, <etal>et al</etal> (2020) <article-title>Serum neurofilament light chain is a discriminative biomarker between frontotemporal lobar degeneration and primary psychiatric disorders</article-title>. <source>J Neurol</source><volume>267</volume>:<fpage>162</fpage>–<lpage>167</lpage>. <pub-id pub-id-type="doi">10.1007/s00415-019-09567-8</pub-id><pub-id pub-id-type="pmid">31595378</pub-id><pub-id pub-id-type="pmcid">PMC6954884</pub-id></mixed-citation></ref><ref id="pone.0236384.ref036"><label>36</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ducharme</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Dols</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Laforce</surname><given-names>R</given-names></name>, <etal>et al</etal> (<year>2020</year>) <article-title>Recommendations to distinguish behavioural variant frontotemporal dementia from psychiatric disorders</article-title>. <source>Brain</source><volume>143</volume>(<issue>6</issue>):<fpage>1632</fpage>–<lpage>1650</lpage>. <pub-id pub-id-type="doi">10.1093/brain/awaa018</pub-id><pub-id pub-id-type="pmid">32129844</pub-id><pub-id pub-id-type="pmcid">PMC7849953</pub-id></mixed-citation></ref><ref id="pone.0236384.ref037"><label>37</label><mixed-citation publication-type="journal"><name name-style="western"><surname>van der Ende</surname><given-names>EL</given-names></name>, <name name-style="western"><surname>Meeter</surname><given-names>LH</given-names></name>, <name name-style="western"><surname>Poos</surname><given-names>JM</given-names></name>, <etal>et al</etal> (<year>2019</year>) <article-title>Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study</article-title>. <source>Lancet Neurol</source><volume>18</volume>:<fpage>1103</fpage>–<lpage>1111</lpage>. <pub-id pub-id-type="doi">10.1016/S1474-4422(19)30354-0</pub-id><pub-id pub-id-type="pmid">31701893</pub-id></mixed-citation></ref><ref id="pone.0236384.ref038"><label>38</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Schroeter</surname><given-names>ML</given-names></name>, <name name-style="western"><surname>Raczka</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Neumann</surname><given-names>J</given-names></name>, <name name-style="western"><surname>von Cramon</surname><given-names>DY</given-names></name> (<year>2008</year>) <article-title>Neural networks in frontotemporal dementia-A meta-analysis</article-title>. <source>Neurobiol Aging</source><volume>29</volume>:<fpage>418</fpage>–<lpage>426</lpage>. <pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2006.10.023</pub-id><pub-id pub-id-type="pmid">17140704</pub-id></mixed-citation></ref><ref id="pone.0236384.ref039"><label>39</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Dopper</surname><given-names>EGP</given-names></name>, <name name-style="western"><surname>Rombouts</surname><given-names>SARB</given-names></name>, <name name-style="western"><surname>Jiskoot</surname><given-names>LC</given-names></name>, <etal>et al</etal> (<year>2014</year>) <article-title>Structural and functional brain connectivity in presymptomatic familial frontotemporal dementia</article-title>. <source>Neurology</source><volume>83</volume>:<fpage>e19</fpage>–<lpage>e26</lpage>. <pub-id pub-id-type="doi">10.1212/WNL.0000000000000583</pub-id><pub-id pub-id-type="pmid">25002573</pub-id></mixed-citation></ref><ref id="pone.0236384.ref040"><label>40</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Steinacker</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Feneberg</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Weishaupt</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>2016</year>) <article-title>Neurofilaments in the diagnosis of motoneuron diseases: A prospective study on 455 patients</article-title>. <source>J Neurol Neurosurg Psychiatry</source><volume>87</volume>:<fpage>12</fpage>–<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1136/jnnp-2015-311387</pub-id><pub-id pub-id-type="pmid">26296871</pub-id></mixed-citation></ref><ref id="pone.0236384.ref041"><label>41</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Meeter</surname><given-names>LHH</given-names></name>, <name name-style="western"><surname>Gendron</surname><given-names>TF</given-names></name>, <name name-style="western"><surname>Sias</surname><given-names>AC</given-names></name>, <etal>et al</etal> (<year>2018</year>) <article-title>Poly(GP), neurofilament and grey matter deficits in C9orf72 expansion carriers</article-title>. <source>Ann Clin Transl Neurol</source><volume>5</volume>:<fpage>583</fpage>–<lpage>597</lpage>. <pub-id pub-id-type="doi">10.1002/acn3.559</pub-id><pub-id pub-id-type="pmid">29761121</pub-id><pub-id pub-id-type="pmcid">PMC5945959</pub-id></mixed-citation></ref><ref id="pone.0236384.ref042"><label>42</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Neumann</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Sampathu</surname><given-names>DM</given-names></name>, <name name-style="western"><surname>Kwong</surname><given-names>LK</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis</article-title>. <source>Science</source><volume>314</volume>:<fpage>130</fpage>–<lpage>133</lpage>. <pub-id pub-id-type="doi">10.1126/science.1134108</pub-id><pub-id pub-id-type="pmid">17023659</pub-id></mixed-citation></ref><ref id="pone.0236384.ref043"><label>43</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Hardiman</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Van Den</surname><given-names>Berg LH</given-names></name>, <name name-style="western"><surname>Kiernan</surname><given-names>MC</given-names></name> (<year>2011</year>) <article-title>Clinical diagnosis and management of amyotrophic lateral sclerosis</article-title>. <source>Nat Rev Neurol</source><volume>7</volume>:<fpage>639</fpage>–<lpage>649</lpage>. <pub-id pub-id-type="doi">10.1038/nrneurol.2011.153</pub-id><pub-id pub-id-type="pmid">21989247</pub-id></mixed-citation></ref><ref id="pone.0236384.ref044"><label>44</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Sreedharan</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Blair</surname><given-names>IP</given-names></name>, <name name-style="western"><surname>Tripathi</surname><given-names>VB</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>TDP-43 Mutations in Familial and Sporadic Amyotrophic Lateral Sclerosis</article-title>. <source>Science</source><volume>319</volume>:<fpage>1668</fpage>–<lpage>1672</lpage>. <pub-id pub-id-type="doi">10.1126/science.1154584</pub-id><pub-id pub-id-type="pmid">18309045</pub-id><pub-id pub-id-type="pmcid">PMC7116650</pub-id></mixed-citation></ref><ref id="pone.0236384.ref045"><label>45</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Spinelli</surname><given-names>EG</given-names></name>, <name name-style="western"><surname>Mandelli</surname><given-names>ML</given-names></name>, <name name-style="western"><surname>Miller</surname><given-names>ZA</given-names></name>, <etal>et al</etal> (<year>2017</year>) <article-title>Typical and atypical pathology in primary progressive aphasia variants</article-title>. <source>Ann Neurol</source><volume>81</volume>:<fpage>430</fpage>–<lpage>443</lpage>. <pub-id pub-id-type="doi">10.1002/ana.24885</pub-id><pub-id pub-id-type="pmid">28133816</pub-id><pub-id pub-id-type="pmcid">PMC5421819</pub-id></mixed-citation></ref><ref id="pone.0236384.ref046"><label>46</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Spotorno</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Hall</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Irwin</surname><given-names>DJ</given-names></name>, <etal>et al</etal> (<year>2019</year>) <article-title>Diffusion Tensor MRI to Distinguish Progressive Supranuclear Palsy from α-Synucleinopathies</article-title>. <source>Radiology</source><volume>293</volume>:<fpage>646</fpage>–<lpage>653</lpage>. <pub-id pub-id-type="doi">10.1148/radiol.2019190406</pub-id><pub-id pub-id-type="pmid">31617796</pub-id><pub-id pub-id-type="pmcid">PMC6889922</pub-id></mixed-citation></ref><ref id="pone.0236384.ref047"><label>47</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Acosta-Cabronero</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Alley</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Williams</surname><given-names>GB</given-names></name>, <name name-style="western"><surname>Pengas</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Nestor</surname><given-names>PJ</given-names></name> (<year>2012</year>) <article-title>Diffusion Tensor Metrics as Biomarkers in Alzheimer’s Disease</article-title>. <source>PLoS One</source>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0049072</pub-id><pub-id pub-id-type="pmcid">PMC3492261</pub-id><pub-id pub-id-type="pmid">23145075</pub-id></mixed-citation></ref><ref id="pone.0236384.ref048"><label>48</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Westin</surname><given-names>CF</given-names></name>, <name name-style="western"><surname>Knutsson</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Pasternak</surname><given-names>O</given-names></name>, <etal>et al</etal> (<year>2016</year>) <article-title>Q-space trajectory imaging for multidimensional diffusion MRI of the human brain</article-title>. <source>Neuroimage</source><volume>135</volume>:<fpage>345</fpage>–<lpage>362</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroimage.2016.02.039</pub-id><pub-id pub-id-type="pmid">26923372</pub-id><pub-id pub-id-type="pmcid">PMC4916005</pub-id></mixed-citation></ref><ref id="pone.0236384.ref049"><label>49</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Eriksson</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Lasic</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Topgaard</surname><given-names>D</given-names></name> (<year>2013</year>) <article-title>Isotropic diffusion weighting in PGSE NMR by magic-angle spinning of the q-vector</article-title>. <source>J Magn Reson</source><volume>226</volume>:<fpage>13</fpage>–<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1016/j.jmr.2012.10.015</pub-id><pub-id pub-id-type="pmid">23178533</pub-id></mixed-citation></ref><ref id="pone.0236384.ref050"><label>50</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Shemesh</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Özarslan</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Komlosh</surname><given-names>ME</given-names></name>, <name name-style="western"><surname>Basser</surname><given-names>PJ</given-names></name>, <name name-style="western"><surname>Cohen</surname><given-names>Y</given-names></name> (<year>2010</year>) <article-title>From single-pulsed field gradient to double-pulsed field gradient MR: Gleaning new microstructural information and developing new forms of contrast in MRI</article-title>. <source>NMR Biomed</source><volume>23</volume>:<fpage>757</fpage>–<lpage>780</lpage>. <pub-id pub-id-type="doi">10.1002/nbm.1550</pub-id><pub-id pub-id-type="pmid">20690130</pub-id><pub-id pub-id-type="pmcid">PMC3139994</pub-id></mixed-citation></ref><ref id="pone.0236384.ref051"><label>51</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Lampinen</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Szczepankiewicz</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Novén</surname><given-names>M</given-names></name>, <name name-style="western"><surname>van Westen</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Hansson</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Englund</surname><given-names>E</given-names></name>, <etal>et al</etal> (<year>2019</year>) <article-title>Searching for the neurite density with diffusion MRI: Challenges for biophysical modeling</article-title>. <source>Hum Brain Mapp</source><volume>40</volume>:<fpage>2529</fpage>–<lpage>2545</lpage>. <pub-id pub-id-type="doi">10.1002/hbm.24542</pub-id><pub-id pub-id-type="pmid">30802367</pub-id><pub-id pub-id-type="pmcid">PMC6503974</pub-id></mixed-citation></ref></ref-list></back><sub-article id="pone.0236384.r001" article-type="aggregated-review-documents"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0236384.r001</article-id><title-group><article-title>Decision Letter 0</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Najbauer</surname><given-names initials="J">Joseph</given-names></name><role>Academic Editor</role></contrib></contrib-group><permissions><copyright-statement>© 2020 Joseph Najbauer</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Joseph Najbauer</copyright-holder><license xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><related-article xmlns:xlink="http://www.w3.org/1999/xlink" id="rel-obj001" ext-link-type="doi" xlink:href="10.1371/journal.pone.0236384" related-article-type="reviewed-article"/><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>0</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="letter-date">14 Aug 2020</named-content>
</p><p>Pécs, Hungary</p><p>August 13, 2020</p><p>PONE-D-20-20650</p><p>Plasma neurofilament light protein correlates with diffusion tensor imaging metrics in frontotemporal dementia</p><p>PLOS ONE</p><p>Dear Dr. Spotorno,</p><p>Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised by the Reviewers, listed below.</p><p>Please submit your revised manuscript by Sep 28 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <email>plosone@plos.org</email>. When you're ready to submit your revision, log on to <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.editorialmanager.com/pone/">https://www.editorialmanager.com/pone/</ext-link> and select the 'Submissions Needing Revision' folder to locate your manuscript file.</p><p>Please include the following items when submitting your revised manuscript:</p><p><list list-type="bullet"><list-item><p>A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.</p></list-item><list-item><p>A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.</p></list-item><list-item><p>An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.</p></list-item></list></p><p>If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.</p><p>If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols">http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols</ext-link></p><p>We look forward to receiving your revised manuscript.</p><p>Kind regards,</p><p>Joseph Najbauer, Ph.D.</p><p>Academic Editor</p><p>PLOS ONE</p><p>--------------------------------------------------------</p><p>Journal Requirements:</p><p>When submitting your revision, we need you to address these additional requirements.</p><p>1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at</p><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf">https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf</ext-link> and</p><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf">https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf</ext-link></p><p>2. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions">http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions</ext-link>.</p><p>In your revised cover letter, please address the following prompts:</p><p>a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.</p><p>b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.bmj.com/content/340/bmj.c181.long">http://www.bmj.com/content/340/bmj.c181.long</ext-link> for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories">http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories</ext-link>.</p><p>We will update your Data Availability statement on your behalf to reflect the information you provide.</p><p>3. Thank you for including your competing interests statement; "I have read the journal's policy and the authors of this manuscript have the following competing interests: HZ has served at scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed and CogRx, has given lectures in symposia sponsored by Fujirebio, Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. . KB has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Roche Diagnostics, and Siemens Healthineers, and is also a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS)."</p><p>Please confirm that this does not alter your adherence to all PLOS ONE policies on sharing data and materials, by including the following statement: "This does not alter our adherence to  PLOS ONE policies on sharing data and materials.” (as detailed online in our guide for authors <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="about:blank">http://journals.plos.org/plosone/s/competing-interests</ext-link>).  If there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.</p><p>Please include your updated Competing Interests statement in your cover letter; we will change the online submission form on your behalf.</p><p>Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="about:blank">http://journals.plos.org/plosone/s/competing-interests</ext-link></p><p>4. Please amend either the abstract on the online submission form (via Edit Submission) or the abstract in the manuscript so that they are identical.</p><p>5.  Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="about:blank">http://journals.plos.org/plosone/s/supporting-information</ext-link>.</p><p>[Note: HTML markup is below. Please do not edit.]</p><p>Reviewers' comments:</p><p>Reviewer's Responses to Questions</p><p><bold>Comments to the Author</bold></p><p>1. Is the manuscript technically sound, and do the data support the conclusions?</p><p>The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. </p><p>Reviewer #1: Yes</p><p>Reviewer #2: Yes</p><p>**********</p><p>2. Has the statistical analysis been performed appropriately and rigorously? </p><p>Reviewer #1: Yes</p><p>Reviewer #2: Yes</p><p>**********</p><p>3. Have the authors made all data underlying the findings in their manuscript fully available?</p><p>The <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.plosone.org/static/policies.action#sharing">PLOS Data policy</ext-link> requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.</p><p>Reviewer #1: Yes</p><p>Reviewer #2: Yes</p><p>**********</p><p>4. Is the manuscript presented in an intelligible fashion and written in standard English?</p><p>PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.</p><p>Reviewer #1: Yes</p><p>Reviewer #2: Yes</p><p>**********</p><p>5. Review Comments to the Author</p><p>Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)</p><p>Reviewer #1: In their manuscript, Spotorno and colleagues describe the relationship between NfL levels in blood and white matter integrity as measured by DTI in a small cohort of bvFTD patients. The relevance of the study is clear and the methods and statistical analyses seem appropriate. The manuscript is generally well written. I have some minor comments:</p><p>Introduction</p><p>In the paragraph starting with ‘The present study…’, the authors mention previous studies of white matter integrity in FTD. I suggest the authors clarify which measures of white matter were used. Is this based on neuroimaging measures other than those extracted from DTI?</p><p>Methods</p><p>- The methods section mentions that the data is derived from a longitudinal FTD study. Did participants also undergo repeated MRI scans and blood sampling? If so, it would be of interest to investigate whether NfL levels also predict subsequent decline in white matter measures.</p><p>- The small sample size makes the reader question whether many patients were excluded from this study, and if so, for what reason. Can you specify this more clearly?</p><p>- Table 1: were the definite cases autopsy-proven or genetic cases?</p><p>- Table 1: besides standard deviation, can you provide the range of the interval between plasma and MRI? This is important for interpretation of the results.</p><p>Results</p><p>- In the voxel-wise TBSS analysis, it seems surprising that there are negative correlations between NfL and FA but not with other DTI measures. I suggest some comment on this in the discussion section.</p><p>Reviewer #2: In this manuscript, Spotorno and coll show their findings on a potential relationship between plasma NfL levels and involvement of white matter tracts in bvFTD. These data are very interesting and deal with a very current topic. As a further strong point, the manuscrpit is well written with a thorough data discussion. I'd just add results of a direct comparison of NFl serum levels between patients and controls. Moreover, I would be interested to know if bvFTD patients were examined for motor involvement and, if yes, I'd also add a specific correlation analysis with the CST DTI values.</p><p>**********</p><p>6. PLOS authors have the option to publish the peer review history of their article (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history">what does this mean?</ext-link>). If published, this will include your full peer review and any attached files.</p><p>If you choose “no”, your identity will remain anonymous but your review may still be made public.</p><p><bold>Do you want your identity to be public for this peer review?</bold> For information about this choice, including consent withdrawal, please see our <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.plos.org/privacy-policy">Privacy Policy</ext-link>.</p><p>Reviewer #1: No</p><p>Reviewer #2: No</p><p>[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]</p><p>While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pacev2.apexcovantage.com/">https://pacev2.apexcovantage.com/</ext-link>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <email>figures@plos.org</email>. Please note that Supporting Information files do not need this step.</p></body></sub-article><sub-article id="pone.0236384.r002" article-type="author-comment"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0236384.r002</article-id><title-group><article-title>Author response to Decision Letter 0</article-title></title-group><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="editor-report" id="rel-obj002" xml:lang="en" ext-link-type="doi" xlink:href="10.1371/journal.pone.0236384"/><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>1</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="author-response-date">24 Sep 2020</named-content>
</p><p>Dear prof. Najbauer,</p><p>Thank you for your consideration of our work. We provide here a point-by-point description of response to reviewer comments below. For your convenience the major changes in the text of the revised manuscript are provided below in italics and highlighted in the revised manuscript.</p><p>Journal Requirements</p><p> • Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming.</p><p>We have checked PLOS ONE’s style requirements and edited the manuscript accordingly.</p><p> • We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly.</p><p>The justification of the restricted access to the original data has been included into the revised cover letter.</p><p> • Update the conflict of interest statement.</p><p>The conflict of interests statement has been updated in the manuscript and reported in the revised cover letter.</p><p> • Please amend either the abstract on the online submission form (via Edit Submission) or the abstract in the manuscript so that they are identical.</p><p> We have updated the abstract on the online submission form.</p><p> • Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly.</p><p>The captions of the supporting information have been added to the manuscript and the in-text citations have been updated.</p><p>Page (21)</p><p>Supporting information captions</p><p>S1 Appendix: Tracts of interest analysis: Comparison of FA values between bvFTD and healthy controls</p><p>S2 Appendix: Tracts of interest analysis: Association between FA and plasma NfL levels in the tracts that exhibited a reduction in FA in the bvFTD cohort</p><p>Reviewer 1</p><p>In their manuscript, Spotorno and colleagues describe the relationship between NfL levels in blood and white matter integrity as measured by DTI in a small cohort of bvFTD patients. The relevance of the study is clear and the methods and statistical analyses seem appropriate. The manuscript is generally well written. I have some minor comments.</p><p>We thank this reviewer for this overall positive appraisal of the importance and rigor of our work.</p><p> • Introduction: In the paragraph starting with ‘The present study…’, the authors mention previous studies of white matter integrity in FTD. I suggest the authors clarify which measures of white matter were used. Is this based on neuroimaging measures other than those extracted from DTI?</p><p>Thanks for the important question. We have updated the introduction in order to clarify which metrics have been used in the literature. The studies we referred to quantified DTI metrics or combined tensor based tractography with the quantification of DTI metrics such as FA.</p><p>Please see the changes in the Introduction section of the revised manuscript.</p><p>Page 4</p><p>“Previous studies on FTD based on the quantification of DTI metrics [20–22] as well as on a combination of tensor based tractography and quantification of DTI metrics [23] have indeed showed extensive pattern of white matter involvement including the fronto-occipital fasciculus, the superior longitudinal fasciculus, the uncinate fasciculus, the dorsal cingulum bundle, the anterior thalamic radiation, and the inferior / hippocampal portion of the cingulum bundle. We also included in our analysis tracts in which degeneration has been reported to correlate with NfL level in previous DTI studies, in particular the cortico-spinal tract [16,19]⁠.”</p><p> • The methods section mentions that the data is derived from a longitudinal FTD study. Did participants also undergo repeated MRI scans and blood sampling? If so, it would be of interest to investigate whether NfL levels also predict subsequent decline in white matter measures.</p><p>Sadly, longitudinal MRI and blood sampling were not collected as part of the current study. We have added this information to the methods section: </p><p>Page 5</p><p>”The LUPROFS protocol includes clinical examination, caregiver history, symptom rating, neuropsychological examination, standardized neurological examination, and, at baseline, CSF and blood sample and MRI”</p><p> • The small sample size makes the reader question whether many patients were excluded from this study, and if so, for what reason. Can you specify this more clearly?</p><p>Thank you for this important comment. Although the sample size is limited, this is roughly what is expected based on the population size of the catchment area of the study, and the inherent difficulty of conducting research on patients with frontotemporal dementia which are, not seldom, uncooperative. Based on our own epidemiological research (Nilsson et al 2014, Plos One), in our catchments area 36 FTD individuals are expected to develop FTD during the period in which the LUPROFS study was conducted. In addition, patients were also referred from neighboring areas since our unit served as tertiary center for neurodegenerative diseases. The total number of bvFTD patients included in the LUPRUFS study was 41 (including possible, probable and definite cases). However, only 20 fulfilled the inclusion criteria of this specific study. We agree that it is critical to clarify the inclusion/exclusion procedure and we have updated the method section accordingly: </p><p>Page 5</p><p>”The participants took part in the Lund Prospective Frontotemporal Dementia Study (LUPROFS), a longitudinal study of patients with any of the frontotemporal dementia spectrum disorders which included patients from 2009 to 2014 at the Memory Clinic of Skåne University Hospital in Lund, Sweden”</p><p>“The exclusion criteria included: &gt; 3 lacunar strokes or any number of other type of strokes visible on MRI examination, alcohol addiction, or any other significant neurological or psychiatric comorbidity. Patients were included in the present study only if they had a clinical diagnosis of probable or definite bvFTD, underwent MRI successfully with all relevant sequences to this study, and underwent MRI within a year from blood sampling. Twenty of the 41 subjects with bvFTD included in the LUPROFS cohort, could be included in the present study.”</p><p> • Table 1: were the definite cases autopsy-proven or genetic cases?</p><p>Thank you for the important question. The information has been added to Table 1.</p><p> Page 6</p><p> “6 patients fulfill definite bvFTD criteria according to neuropathological examination, 2 according to genetic examination, and one according to both.”</p><p> • Table 1: besides standard deviation, can you provide the range of the interval between plasma and MRI? This is important for interpretation of the results.</p><p> The interval between plasma collection and MRI scan range between 0 and 10 months. This information has been added to Table 1.</p><p> • In the voxel-wise TBSS analysis, it seems surprising that there are negative correlations between NfL and FA but not with other DTI measures. I suggest some comment on this in the discussion section.</p><p>Thank you for highlighting this important point. It is indeed unusual that a single DTI metric is associated with a variable while the other metric are not. It has been reported that DTI metrics could be differentially sensitive to biological and pathological processes. However, we prefer to not speculate on this difference because associations between NfL levels and other DTI metrics could be hidden by the relative low statistical power of the current study and they could emerge in studies with bigger cohorts. Moreover, the tensor model is not suited to support the biological interpretation of specific metrics. We have included these considerations the discussion session of the revised manuscript.</p><p> Page 15</p><p>“Moreover, the lack of association between plasma NfL levels and DTI metrics other than FA in the TBSS analysis is surprising when considering the extent of the association between NfL levels and FA values. A follow up study in a bigger cohort is warranted to investigate whether, with greater statistical power, associations with other metrics would emerge. Different DTI metrics could also be differently sensitive to different biological process. For example, FA appears to distinguish between progressive supranuclear palsy and Parkinson’s disease with higher level of accuracy than other DTI metrics [46]⁠⁠⁠, while axial and mean diffusivity seem to be the first DTI-related abnormalities to occur in Alzheimer’s disease [47]⁠. However, one should bear in mind that, although DTI metrics are sensitive to pathological processes in white matter, they cannot be interpreted as a direct proxy of a specific biological process like axonal degeneration, which is the likely cause of the increased peripheral levels of NfL. A measure such as FA is, indeed, sensitive both to anisotropy, which is caused by the presence of elongated cell structures, like axons, and orientation dispersion, which is caused by fanning or crossing fibers [48]⁠⁠. Therefore, DTI cannot pinpoint the biological bases of a reduction in FA nor reflect the complexity of white matter organization. Alternative acquisition strategies have been proposed [48–50]⁠⁠ but the estimation of an exact biologic property remains challenging despite the use of both advanced DWI sequences and modeling [51]⁠⁠.”</p><p>Reviewer 2</p><p>In this manuscript, Spotorno and coll show their findings on a potential relationship between plasma NfL levels and involvement of white matter tracts in bvFTD. These data are very interesting and deal with a very current topic. As a further strong point, the manuscrpit is well written with a thorough data discussion.</p><p>We thank this reviewer for the positive feedback on our work.</p><p> • I'd just add results of a direct comparison of NFl serum levels between patients and controls. Moreover, I would be interested to know if bvFTD patients were examined for motor involvement and, if yes, I'd also add a specific correlation analysis with the CST DTI values.</p><p>Although the comparison of NfL levels between patients and controls was beyond the purpose of the present study and that elevated peripheral levels of NfL in FTD have been reported in previous studies (e.g, Olsson et al., 2019, JAMA Neurol; Meeter et al., 2019, J Neurol Neurosurg Psychiatry; Landqvist Waldö et al., 2013, BMC Neurol.) we agree that the comparison between NfL in plasma between FTD patients and controls iscertainly is an important topic and the lack of such comparison in the current cohort is a limitation which have been included in the discussion of the revised manuscript.</p><p>Page 15</p><p>“ Increased peripheral NfL has now been reliably validated in FTD [8–13] and was not a purpose of the current study; however the lack of a direct comparison of plasma NfL levels between bvFTD and healthy controls is also a limitation of the present study.”</p><p>The FTD patients were examined for motor involvement but, regrettably, only in a clinical routine protocol without using any standardized measurement scale. Thus, any quantitative analysis, such as the correlational analysis suggested, cannot be performed in the present chort. However, one patient had a FTD MND diagnosis. This is explicitly mentioned in the methods section of the revised manuscript.</p><p>Page 5 </p><p>“No standardized assessment of motor functions was performed as part of the study, however, one patient had a diagnosis of FTD with motor neuron disease (FTD-MND according to the Awji criteria [25])”</p><supplementary-material content-type="local-data" id="pone.0236384.s003" position="float" orientation="portrait"><label>Attachment</label><caption><p>Submitted filename: <named-content content-type="submitted-filename">responses_to_reviewers.docx</named-content></p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pone.0236384.s003.docx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></body></sub-article><sub-article id="pone.0236384.r003" article-type="editor-report"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0236384.r003</article-id><title-group><article-title>Decision Letter 1</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Najbauer</surname><given-names initials="J">Joseph</given-names></name><role>Academic Editor</role></contrib></contrib-group><permissions><copyright-statement>© 2020 Joseph Najbauer</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Joseph Najbauer</copyright-holder><license xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="reviewed-article" id="rel-obj003" xml:lang="en" ext-link-type="doi" xlink:href="10.1371/journal.pone.0236384"/><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>1</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="letter-date">12 Oct 2020</named-content>
</p><p>Pécs, Hungary</p><p>October 12, 2020</p><p>Plasma neurofilament light protein correlates with diffusion tensor imaging metrics in frontotemporal dementia</p><p>PONE-D-20-20650R1</p><p>Dear Dr. Spotorno,</p><p>We’re pleased to inform you that your manuscript (R1 version) has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.</p><p>Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.</p><p>An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.editorialmanager.com/pone/">http://www.editorialmanager.com/pone/</ext-link>, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <email>authorbilling@plos.org</email>.</p><p>If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <email>onepress@plos.org</email>.</p><p>Kind regards,</p><p>Joseph Najbauer, Ph.D.</p><p>Academic Editor</p><p>PLOS ONE</p><p>-------------------------------</p><p>Additional Editor Comments:</p><p>PLEASE NOTE: There are extra spaces inserted after reference numbers throughout the manuscript text - please correct.</p></body></sub-article><sub-article id="pone.0236384.r004" article-type="editor-report"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0236384.r004</article-id><title-group><article-title>Acceptance letter</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Najbauer</surname><given-names initials="J">Joseph</given-names></name><role>Academic Editor</role></contrib></contrib-group><permissions><copyright-statement>© 2020 Joseph Najbauer</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Joseph Najbauer</copyright-holder><license xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><related-article xmlns:xlink="http://www.w3.org/1999/xlink" id="rel-obj004" ext-link-type="doi" xlink:href="10.1371/journal.pone.0236384" related-article-type="reviewed-article"/></front-stub><body><p>
<named-content content-type="letter-date">16 Oct 2020</named-content>
</p><p>PONE-D-20-20650R1 </p><p>Plasma neurofilament light protein correlates with diffusion tensor imaging metrics in frontotemporal dementia </p><p>Dear Dr. Spotorno:</p><p>I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. </p><p>If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <email>onepress@plos.org</email>.</p><p>If we can help with anything else, please email us at <email>plosone@plos.org</email>. </p><p>Thank you for submitting your work to PLOS ONE and supporting open access. </p><p>Kind regards, </p><p>PLOS ONE Editorial Office Staff</p><p>on behalf of</p><p>Dr. Joseph Najbauer </p><p>Academic Editor</p><p>PLOS ONE</p></body></sub-article></article>